msgid ""
msgstr ""
"Project-Id-Version: zh-article.po 1.0\n"
"PO-Revision-Date: YEAR-MO-DA HO:MI +ZONE\n"
"Last-Translator: FULL NAME <EMAIL@ADDRESS>\n"
"Language-Team: LANGUAGE <LL@li.org>\n"
"MIME-Version: 1.0\n"
"Content-Type: text/plain; charset=Windows-1252\n"
"Content-Transfer-Encoding: 8bit\n"


# ARTICLE TITLE
#: 9287 TITLE
msgid "Welcome to the new LAMsight "
msgstr "欢迎来到 LAMsight 的新网站 "

# ARTICLE CONTENT
#: 9287 CONTENT
msgid "<h3>Quick Start</h3>\n\nThere are 3 things you can do to help us prepare to introduce the site to researchers:\n\n<ul>\n<li> Enter your preferences (under User Options to the right)</li><p>\n<li> Fill out these four surveys\n   <ul> \n   <li> <a href="/dashboard/collect/survey/6136">LAM Diagnosis</a>\n   <li> <a href="/dashboard/collect/survey/6055">Existing Medical Information</a>\n   <li> <a href="/dashboard/collect/survey/5988">Behaviour and Environment</a>\n   <li> <a href="/dashboard/collect/survey/6072">Reproductive Health</a>\n   </ul><p>\n</li>\n<li> Provide feedback in the <a href="/dashboard/discuss/">discussion forums</a></li>\n</ul>\n\nPlease start by completing the preferences section of the site first. Use the link on the right side of the page.  Completing this section is essential to helping us understand who you are and how we can best communicate.<p>\n\n<h3>Main Site Features</h3>\n\nThere are 3 ways to interact with LAMsight. Each area is accessed by clicking on the green menu buttons at the top of the screen.<p>\n\n<ul>\n<li> <b>Collect</b> - The “Collect” section of the site enables information capture. This is at the heart of the core goal of LAMsight – to aggregate disease information about the global LAM patient population in a way that both enables researchers to generate new insights into the disease and treatment and that can be updated as research questions change and as the importance of certain symptoms becomes clearer. The information provided is to be used by both patients and researchers as they try to better understand the causes and treatments for the disease. This section consists of a interactive surveys that adapt to the questions you answer as you answer them.  Because, we are striving to improve these surveys continuously, we ask that you click on the comment icon next to each question in order to provide us with feedback about the question and if you felt that question was clear, useful, interesting etc.<p>\n\n<li> <b>Explore</b> - The “Explore” section of the site is an interface for looking at data in collective or aggregated form compiled from the questions that patients answer individually. We are working on a significant enhancement of this feature. For now, the main functionality enables patients or researchers to search for a keyword from a survey question. Search results summarize the number and content of responses collected from participants on any given question.<p>\n\n<li> <b>Discuss</b> - The “Discuss” section of the site allows all users to discuss surveys, ask questions, share observations and get help. You can enter posts in each of these respective discussion areas or create a new discussion topic by posting it in the Discussion area. If you have support related issues, the LAMsight administrative team will aim to reply to your post within 24 hours.  \n\n</ul>\n\n<h3>Ongoing Site Enhancement</h3> \n\nIn our ongoing work to enhance LAMsight, we will be focusing on new ways for researchers and patients to collaborate through data collection, surveys created by patients for other patients and by researchers for patients, etc.. Please let us know if there are ways that you think this site can be improved to better facilitate progress in LAM research. <p>\n\n<h3>What’s Coming Next?</h3>\n\nTo the right you will see an ongoing record of progress and site enhancements. We are working to improve the support for multiple languages for the most important site content.  <p>\n\nThank you for your collaboration in this important project. Your help makes progress in LAM research possible!\n\nThe LAMsight Administrators \n"
msgstr "<h3>快速启动</h3>\n\n您可以通过做以下 3 类工作来帮助我们把本网站介绍给研究者：\n\n<ul>\n<li> 输入您的首选项（在用户选项右侧输入）</li><p>\n<li> 填写网站中的四份调查问卷\n   <ul> \n   <li> <a href="/dashboard/collect/survey/6136">LAM 诊断</a>\n   <li> <a href="/dashboard/collect/survey/6055">现有医疗信息</a>\n   <li> <a href="/dashboard/collect/survey/5988">生活习惯和环境因素</a>\n   <li> <a href="/dashboard/collect/survey/6072">生殖健康</a>\n   </ul><p>\n</li>\n<li> 将反馈信息发到 <a href="/dashboard/discuss/">论坛上</a></li>\n</ul>\n\n请先从填写网站的用户首选项部分开始。请点击页面右侧的链接。填写本部分内容非常重要，因为它可以帮助我们了解您的情况以及与您沟通的最佳途径。<p>\n\n<h3>网站主要功能</h3>\n\n您可以通过 3 种途径与 LAMsight 网站互动交流。点击屏幕顶端的绿色菜单按钮即可进入网站内的各分区。<p>\n\n<ul>\n<li> <b>收集</b> - 网站的“收集”部分用于获取信息。这一功能是 LAMsight 网站的核心目标的关键所在——通过一种全新的途径来收集全球 LAM 患者族群的疾病信息，这样一来，既可以使研究者形成对疾病和治疗方法的新见解，又可以通过研究提问的变化以及随着一些病症的重要性的日益明显化使得这些见解得以不断更新。本网站的信息可供患者和研究者共同使用，以便研究者更好地认识疾病的病因和相应的治疗方法。本部分包含一份互动式问卷，它可根据您对问题的回答来调整提问内容。由于我们正在努力以不断改进这些调查问卷，所以请您在填写的同时点击每个提问旁边的“评论”图标以向我们反馈您对这些提问的看法，例如它们是否清楚、实用、有趣等等。<p>\n\n<li> <b>探索</b> - 网站的“探索”部分是一个界面，通过该界面可以集中式或批量式地查看患者们独立回答的问卷问题。我们正努力以显著优化这一功能。目前，该部分的主要功能是使得患者或研究者通过查询问卷问题中的某个关键字进行数据搜索。搜索结果会总结了从调查参与者处收集的对于任何一个给定问题的回答数量和内容。<p>\n\n<li> <b>讨论</b> - 网站的“讨论”部分为用户提供一个讨论问卷、提出问题、分享观点和寻求帮助的平台。您可以在上述各个讨论区中发帖，或在“讨论”部分创建新的讨论话题。如果您发帖支持 LAMsight 网站相关工作，网站的管理团队将力争在 24 小时内回复您的帖子。\n\n</ul>\n\n<h3>网站进一步优化</h3> \n\n在进一步优化 LAMsight 网站的过程中，我们将重点开发新途径以使研究者和患者能通过数据收集、患者或研究者为其他患者编写问卷的形式进行协作。如果您认为本网站需要改进以更好地为 LAM 研究服务，请及时与我们沟通。<p>\n\n<h3>下一项是什么？</h3>\n\n在页面右侧您可以看到不断更新的研究进展和网站优化记录。我们正在努力实现网站首要内容的多语言化。<p>\n\n感谢您对本项重要研究计划的大力协作。您的支持是 LAM 研究前进的动力！\n\nLAMsight 管理员 \n"

# ARTICLE TITLE
#: 22404 TITLE
msgid "About LAMsight"
msgstr "关于 LAMsight"

# ARTICLE CONTENT
#: 22404 CONTENT
msgid "About LAMsight\n--------------\n\nLAMsight is a centralized database that will enable new forms of information-gathering and collaboration by patients, family members, clinicians, and researchers. Its goal is to overcome the barriers that researchers face in accessing up-to-date data about the global LAM population. LAMsight enables idea-generation by researchers through information exchange between patients and researchers in “real time”.<br><br>\n\nThe ultimate aim of LAMsight is to support more efficient and effective design and implementation of clinical trials for LAM patients. Another goal is to lower the cost and time associated with research efforts to learn about larger samples of LAM patients. LAMsight will open up the world of LAM research to a broader research and clinical community. It can also help patients share new aspects of the disease that may be relevant to treatment. This effort was led by the [New Media Medicine][1] group of the [MIT Media Laboratory][2] in cooperation with the [LAM Treatment Alliance][3] and the [Dana Farber Cancer Institute][4].<br><br>\n\n\n  [1]: http://newmed.lamtreatmentalliance.org/ "New Media Medicine"\n  [2]: http://www.lamtreatmentalliance.org/ "MIT Media Laboratory"\n  [3]: http://www.curelam.org/ "LAM Treatment Alliance"\n  [4]: http://www.dana-farber.com/ "Dana Farber Cancer Institute""
msgstr "关于 LAMsight\n--------------\n\nLAMsight 是一个集中的数据库，它能让患者、患者家属、医生和研究者通过崭新的形式进行信息收集和相互协作。它的目标是帮助研究者克服获取全球 LAM 患者族群最新数据过程中的障碍。LAMsight 通过患者和研究者的“实时”信息交流，激发研究者的新思路。<br><br>\n\nLAMsight 的根本目标是为 LAM（淋巴管平滑肌瘤病）患者的临床试验更高效、更有成果地设计和进行提供支持。它的另一个目标是减少为了研究更大的 LAM 患者样本所付出的成本和时间。LAMsight 将把 LAM 研究带入更广泛的研究和临床研究团体之中。它还能帮助患者了解与疾病治疗有关的最新观点。上述工作是由 [麻省理工学院媒体实验室] [2] 下属的[新媒体医疗][1] 小组与 [LAM 治疗联盟][3] 和 [Dana Farber 癌症研究所][4]联合开展的。<br><br>\n\n\n  [1]：http://newmed.lamtreatmentalliance.org/ “新媒体医疗”\n  [2]：http://www.lamtreatmentalliance.org/ “麻省理工学院媒体实验室”\n  [3]：http://www.curelam.org/ “LAM 治疗联盟”\n  [4]：http://www.dana-farber.com/ “Dana Farber 癌症研究所”"

# ARTICLE TITLE
#: 22405 TITLE
msgid "Getting Started"
msgstr "开始"

# ARTICLE CONTENT
#: 22405 CONTENT
msgid "Getting Started\n---------------\n\nAre you new to LAMsight? If so, please click the register link above to create a new user account. All that is needed is a valid e-mail address.<br><br>\n\nAfter registration, click the 'Login' link at the very top of this page. Upon successful entry more information will be provided.<br><br>\n\nLAMsight is an evolving project and new functionality and improved usability will occur every few weeks. Updates about the site can be received by setting preferences as described on the login page. By registering now, you are agreeing to receive at least one e-mail letting you know when the site is formally launched with the most important set of features as well as a clear privacy policy and terms of use.<br><br>\n\nIf you joined LAMsight last spring, your user account and any information you entered has been preserved. No re-registration or new registration is needed.  Please contact our support team if you need assistance with lost user accounts or passwords.<br><br>"
msgstr "开始\n---------------\n\n您是首次访问 LAMsight 吗？如果是，请点击上面的“注册”按钮创建新的用户账户。您只需一个有效的电子邮箱地址即可创建。<br><br>\n\n注册后，请点击本页顶端的‘登录’链接。成功登入后您将获得更多信息。<br><br>\n\nLAMsight 是一个不断发展的项目，它每隔数周就会增加新功能并改善使用性。用户可通过登录界面的首选项设置来接收网站更新。通过现在的注册，您同意了至少接收一封电子邮件以让您了解该网站正式开放的时间、它的最主要功能以及清楚的隐私政策和使用条款。<br><br>\n\n如果您在去年春天就加入了 LAMsight，那么本网站仍保留您的账户和您所输入的所有信息。无需再注册或重新注册。如果您忘记用户账户或密码请联系我们的支持团队。<br><br>"

# ARTICLE TITLE
#: 22815 TITLE
msgid "Terms of Use"
msgstr "使用条款"

# ARTICLE CONTENT
#: 22815 CONTENT
msgid "**Terms and Conditions of Use**\n\nEffective September 11th, 2008<br><br>\n\nThe following terms constitute an agreement (the “Agreement”) between you and of the Massachusetts Institute of Technology (“MIT”) on behalf of the MIT Media Laboratory, Inc. (“MIT Media Laboratory”), the operator of www.lamsight.org (the “Site”) and the LAM Treatment Alliance (“LTA”). This agreement governs your use of the Site, both as a casual visitor and a registered member, as described below.<br><br>\n\nBy accessing or using the Site, you agree to be bound by the terms of this Agreement. If you register on the Site as a member, then you will be subject to the terms and conditions for both users and members.<br><br>\n\n\n**Membership Eligibility**\n\nTo become a member and access the area on this Site reserved for members (the “Member Area”), MIT and LTA require that you are either (a) a diagnosed patient of the particular community you are joining, (b) a caregiver for or family member of a patient eligible to join such community, (c) a health care professional (e.g. doctor, nurse, health researcher, etc.), or (d) a guest as authorized by a MIT Media Laboratory or LTA member or employee.<br><br>\n\nChildren under the age of 13 are prohibited from registering as members. By registering as a member you represent that you are age 13 or older.<br><br>\n\nMIT Media Laboratory and LTA have the right at any time to change or discontinue any aspect of this Site, including the content, hours of availability, and equipment needed for access to or use. You understand and agree that this Site is provided to you exclusively under these Terms of Use. MIT Media Laboratory and LTA reserve the right to terminate your account at any time, for any reason, including if either party learns that you have provided false or misleading registration information or have violated the Terms of Use.<br><br>\n\n**This Site Does Not Provide Medical Advice**\n\nAll of the material provided on the Site, such as text, treatments, dosages, outcomes, charts, patient profiles, graphics, photographs, images, advice, messages, forum postings, and any other material provided on the Site are for informational purposes only and are not a substitute for professional medical advice or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding your health. Never disregard professional medical advice or delay in seeking it because of something you have read on this Site.<br><br>\n\nIf you think you may have a medical emergency, call your doctor or 911 immediately. MIT and LTA do not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Site. Reliance on any information provided by MIT or LTA, by persons appearing on the Site at the invitation of MIT or LTA, or by other members is solely at your own risk.<br><br>\n\n**Acceptable and Lawful Use of Site by Members**\n\nMembers shall not post or upload any information or other content on the Site that (a) is false, inaccurate or misleading; (b) is obscene or indecent; (c) infringes any copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy of any party; or (d) is defamatory, libelous, threatening, abusive, hateful, or contains pornography. Members shall not interfere with other members' use and enjoyment of Site. Members may not use the Site to conduct any activity that is illegal or violates the rights of others, provide instructional information about illegal activities, or promote physical harm or injury against any group or individual.<br><br>\n\nAll members represent and warrant that the information they provided when registering as a member, and all information that they subsequently provide regarding themselves and their membership, is true, accurate and not misleading.<br><br>\n\n**Use of Site by Members and Non-Members**\n\nYou may not use any robot, spider, scraper, or other automated means to access the Site or content or services provided on the Site for any purposes. You may not post content on the Site that contains any viruses, Trojan horses, worms, time bombs, spiders, or other computer programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. You shall not attempt to make the Site unavailable through denial-of-service attacks or similar means. You shall not use contact information provided by members, or collect information about our members, to facilitate the sending of unsolicited bulk communications such as SPAM or SPIM or allow others use of your membership account to take such actions.<br><br>\n\nAll the text, images, marks, logos, compilations (meaning the collection, arrangement and assembly of information) of the Web Site, including any Submissions (as defined below), and any of the foregoing sent to you by e-mail or other means (collectively, the “Site Content”) are proprietary to MIT, LTA or to third parties.   Separate provisions apply to Health Data submitted by users and are defined below.<br><br>\n\nMIT and LTA authorize you to view, download, and print the Site Content subject to the following conditions: (a) you may only download and print the Site Content in limited quantities, as required to evaluate whether the good and services displayed on the Web Site are appropriate for your intended use; (b) you may not modify the Site Content; (c) any displays or print outs of the Site Content must be marked “Copyright © 2008 MIT Media Laboratory (New Media Medicine). All rights reserved.”; and (d) you may not remove any copyright, trademark or other proprietary notices that have been placed in the Site Content.  Except as expressly permitted above, copying, modifying reproduction, redistribution, republication, uploading, posting, transmitting, distributing or otherwise exploiting in any way the Site Content, or any portion of the Site Content, is strictly prohibited without the prior written permission of LTA.  In addition, you may not link to any part of the Web Site or any Site Content or frame or otherwise display in any manner the Site Content at any other web site or elsewhere without our prior written consent.<br><br>\n\n**Non-Commercial Use by Members**\n\nThe Member Area and the content and information contained in the Member Area is for the personal use of individual members only and may not be used in connection with any commercial endeavors. Organizations, companies, and/or businesses may not become members and should not use the Site without the written pre-authorization from MIT Media Laboratory or LTA.<br><br>\n\n**Privacy**\n\nYou agree that you have read, understood and accept the terms of MIT Media Laboratory's Privacy Policy, for the use of the Site (the “Privacy Policy”) This Policy governs the collection, use and sharing of personal and non-personal information for all those who elect to use the Site including Submissions.<br><br>\n\n**Submissions**\n\nThe MIT Media Lab and LTA welcome your comments regarding the Site and Site Content.  In the event that you submit ideas, suggestions, materials or other information to MIT Media Lab and LTA, whether at the request of MIT Media Lab and LTA or through your use of the Site (all of the foregoing being “Submissions”), the Submissions will be deemed, and will remain, the sole property of MIT and LTA.  The Submissions will not be treated as confidential by MIT , LTA, or their respective Affiliates (as defined below), nor will such parties be liable for any use or disclosure of any Submissions.  Without limiting the foregoing, MIT and LTA will jointly own all presently known or hereafter existing rights to the Submissions of every kind, in perpetuity, and will be entitled to unrestricted use of the Submissions for any lawful purpose whatsoever, commercial or otherwise, by any means, by any media, without compensation to the provider, author, creator or inventor of the Submissions (the “Participant”).  Each Participant irrevocably and unconditionally waives and covenants not to assert any such rights against MIT and LTA or its affiliates, employees, departments, successors, assigns, licensees, and customers (collectively, “MIT and LTA Affiliates”), as well as any users of the Site.<br><br>\n\n**Posting and Use of Content in the Member Area**\n\nThe Member Area includes community areas, such as forums and other member areas, where members may post messages, images, and other content. If you are a member, you (or the author) own(s) the copyright in the messages, images, and other content you post in the Member Area. However,  by posting such content to the Member Area, you grant MIT Media Laboratory, LTA  and their respective Affiliates the right to use, copy, display, perform, distribute, translate, edit, and create derivative works of your postings, subject to the terms of the Privacy Policy.<br><br>\n\nWhile some community areas in the Member Area are monitored periodically for topicality, MIT and LTA have no obligation to prescreen postings and are not responsible for their content. We encourage you to notify us of inappropriate or illegal content and we reserve the right to remove postings for any reason.<br><br>\n\nYou agree not to disclose to any person or entity personally identifiable information about other members that you learn while using this Site (whether posted in the Member Area by a member or emailed to you by a member) without the written consent of such member. You may disclose information of a general nature that will not reasonably lead to the identification of the member who provided such information or whom such information is about, to third parties outside this Site, subject to the above restriction on non-commercial use.<br><br>\n\n**Member Password and Login Identity**\n\nYou are responsible for maintaining the confidentiality of your member password and login, and are fully responsible for all activities that occur under your password or account with or without your knowledge. If you knowingly provide your login and password information to another person, your membership privileges may be suspended temporarily or terminated. You agree to immediately notify MIT Media Laboratory and LTA of any unauthorized use of your membership password or login or any other breach of security.<br><br>\n\n**Health Data**\n\nThis site encourages you to submit and share data about your health and history.  You have specific rights to any personal health data you have entered including changing, deleting, downloading, and sharing this data.  The use of your data by MIT and LTA are governed by the Privacy Policy.  Your personal data will be used by the Site to construct an aggregate, de-identified view of the patient population.  You agree not to enter personal identifiers into the survey or diary forms of the Site.  Only the preferences section should contain identifiers.<br><br>\n\nHealth Data does not include any information or comments in the forums section which are to be considered public and are governed as described in Submissions above.  Private contact between users can be done via an e-mail exchange to facilitate non-public discourse.<br><br>\n\nHealth data can be removed from future aggregate views on the site, but your prior data will be maintained in an archived, de-identified form.  To have your data and identifiers removed from active use in the system, send an e-mail with your instructions to \nLAMsightHelp@lamtreatmentalliance.org.<br><br>\n\n**Links to Third Party Web Site Are Not Endorsements**\n\nThe Site contains links to third-party web sites.  The linked sites are not under our control, and we are not responsible for the content of any linked site.  We provide these links as a convenience only, and a link does not imply endorsement of, sponsorship of, or affiliation with the linked site by MIT or LTA.  Links to merchants or advertisers are owned and operated by independent retailers or service providers, and therefore, we make no warranties or representations regarding their products, services or business practices.  You are encouraged to exercise appropriate due diligence before proceeding with any transaction with any of these third parties.<br><br>\n\n**Membership Termination**\n\nYou agree that MIT Media Laboratory and LTA may, with or without cause, immediately terminate your membership and access to the Member Area, without prior notice. Without limiting the foregoing, reasons for termination may include, but are not limited to, the following: (a) breaches or violations of this Agreement or other incorporated agreements or policies, (b) requests by law enforcement or other government agencies, (c) a request by you (self-initiated membership cancellation), (d) unexpected technical issues or problems, and (e) extended periods of inactivity. MIT and LTA have no obligation to maintain, store, or transfer information or data to you that you have posted on or uploaded to the Site.<br><br>\n\n**Modifications to this Agreement**\n\nWe reserve the right to modify this Agreement at any time, and without prior notice, by posting amended terms on this Site. We encourage you to review this Agreement periodically for any updates or changes, which will be reflected by the revised date of the Agreement.<br><br>\n\n**Disclaimer of Warranties**\n\nThe Site and the content and services made available on the Site are provided on an “as is” and “as available” basis. MIT and LTA disclaim all express and implied warranties and representations, including, but not limited to, any implied warranty of fitness for a particular purpose, with regard to the Site, the Site content, or any advice or services provided through the Site to the extent permitted by law. MIT and LTA  do not warrant that access to the Site or its content or services will be uninterrupted or error-free or that defects in the Site will be corrected.<br><br>\n\nThe advice, recommendations, information, and conclusions posted or emailed by other members of the Site are not in any way vetted, approved or endorsed by MIT Media Laboratory or LTA. You acknowledge that you use such information at your own risk.<br><br>\n\n**Limitation of Liability**\n\nUnder no circumstances shall MIT, LTA and their respective Affiliates be liable for any indirect, incidental, special, or consequential damages (even if it has been advised of the possibility of such damages) due to your use of this Site or to your reliance on any of the content contained  or the services provided therein.<br><br>\n\n**Indemnification**\n\nYou agree to indemnify, defend,  and hold harmless MIT, LTA and their respective Affiliates, from and against any claims, actions or demands, damages, expenses, liabilities and settlements, including without limitation, attorneys’ fees and other costs incurred or resulting from, or alleged to result from, your violation of this Agreement.<br><br>\n\n**International Users**\n\nMIT and LTA do not warrant that it is appropriate, to download, store or disclose information on the Site outside of the United States (“International Use”), in compliance with the user’s local jurisdiction. Personal information (“Information”) that is submitted to this Site will be collected, processed, stored, disclosed and disposed of in accordance with applicable U.S. law and our Privacy Policy. If you are an International User, you acknowledge and agree that MIT and LTA may collect and use your Information and disclose it to other entities outside your resident jurisdiction. In addition, such Information may be stored on servers located outside your resident jurisdiction. By providing us with your Information, you acknowledge that you consent to the transfer of such Information outside your resident jurisdiction, as detailed in our Privacy Policy. If you do not consent to such transfer, you may not use this Site.<br><br>\n\n**Member Notices**\n\nIf you register as a member, you agree that MIT Media Laboratory and LTA may send notices to you by email at the email address you provide when registering to become a member (or which you later update using the functionality of the Site).<br><br>\n\n**Governing Law and Venue**\n\nThis agreement shall be governed by the laws of the Commonwealth of Massachusetts and the applicable federal laws of the United States of America. All disputes arising under, or resulting from, the membership in or use of the Site, shall be litigated exclusively in the state and federal courts within Suffolk or Middlesex Counties in the Commonwealth of Massachusetts.<br><br>\n\n**Digital Millennium Copyright Act**\n\nThe  Digital Millennium Copyright Act (17 U.S.C. §512, as amended) governs the operation and maintenance of this Site.  Specific instructions regarding notification of infringement can be found on [MIT's DMCA page][1].<br><br>\n\n**No Waiver**\n\nNo delay or failure to act by MIT or LTA in exercising any of its respective rights occurring upon any noncompliance or default by you, with respect to any of the terms and conditions of this Agreement, will impair any such right or be construed to be a waiver thereof, and a waiver by MIT,or LTA of any of the covenants, conditions or agreements to be performed by you, will not be construed to be a waiver of any succeeding breach thereof or of any other covenant, condition or agreement hereof contained.  As used in this Agreement, “including” means “including but not limited to.”<br><br>\n\n**Severability**\n\nIf any provision of this Agreement is found by a court of competent jurisdiction to be invalid, illegal or unenforceable, under any present or future law, then as long as each party’s rights and obligations under this Agreement are not materially or adversely affected thereby, such provisions shall be fully severable, and the remaining provisions of the Agreement will remain in full force and effect to the greatest extent permitted by law.  Except as otherwise expressly provided herein, this Agreement sets forth the entire agreement between you, MIT and LTA, regarding its subject matter, and supersedes all prior promises, agreements or representations, whether written or oral, regarding such subject matter.  You agree that the electronic text of this Agreement constitutes a “writing“, and your assent to the terms and conditions hereof constitutes a “signing” for all purposes.<br><br>\n\n**Use of Name**\n\nUsers of the Site shall not use the name of "MIT", the "Massachusetts Institute of Technology", the "MIT Media Laboratory", or any variation, adaptation or abbreviation thereof, or of any of its trustees, officers, faculty, students, employees or agents, or any trademark owned by MIT, or any terms of this Agreement I any promotional material or public announcement or disclosure, without the prior written consent of MIT’s Technology Licensing Office.<br><br>\n\nThe marks “LTA” and any other trademarked expressions used on this website are proprietary to LTA, and they may not be used in connection with any service or products, other than those provided by LTA, in any manner that is likely to cause confusion among customers, or in any manner that disparages or discredits LTA.  Any use of those marks, or any others displayed on the Web Site, will inure solely to the benefit of their respective owners.<br><br>\n\nAll other brand names and logos that appear throughout LAMsight web pages are marks owned by third parties.<br><br>\n\nAll software used on the Site is proprietary to us or to third parties, and except as may be required to exercise the foregoing license, any redistribution, sale, decompilation, reverse engineering, disassembly, translation or other reduction of such software to human-readable form is prohibited.<br><br>\n\nYou agree, represent and warrant, that your use Site and the Site Content, or any portion thereof, will be consistent with the foregoing license, covenants and restrictions and will neither infringe, nor violate the rights of any other party or breach any contract or legal duty to any other parties.  In addition, you agree that you will comply with all applicable laws and regulations (the “Laws”) relating to the Site, the Site Content or your use of the same, and you will be solely responsible for your violations of any of the Laws.<br><br>\n\n**Assignment**\n\nEither MIT or LTA may assign this Agreement, at any time, to a subsidiary, parent company or a successor to its business, as part of a merger or sale of substantially all of its assets. You may not assign or transfer this Agreement.<br><br>\n\nIf you have questions or comments about our Terms of Use, please contact us at: LAMsightHelp@lamtreatmentalliance.org. You can also direct questions or comments, or violations of this Agreement, to:<br><br>\n\nThe MIT Media Laboratory <br>\nRoom E15-401 c/o Frank Moss <br>\n20 Ames Street <br>\nCambridge, MA 02139<br>\nUSA<br>\n\n\n  [1]: http://web.mit.edu/ist/topics/security/copyright/filing-notice.html "MIT's DMCA page""
msgstr "**使用条款和条件**\n\n2008 年 9 月 11 日起生效<br><br>\n\n下列条款包含您与麻省理工学院 (“MIT”) 所代表的麻省理工学院媒体实验室（“MIT 媒体实验室”）、www.lamsight.org 的经营者（“网站”）和 LAM 治疗联盟 (“LTA”) 所签署的合作协议（“合作协议”）。该协议按照下述条款约束使用本网站的游客和注册用户。<br><br>\n\n一旦您访问或使用本网站，就意味着您同意接受该合作协议的约束。如果您以会员身份注册，则您需要同时遵守用户和会员的条款和条件。<br><br>\n\n\n**会员资格合格性**\n\n如要成为会员并进入网站中只对会员开放的区域（“会员专区”），则需满足 MIT 和 LTA 的要求 (a) 是您所加入的某一特定社团内已被确诊的患者，(b) 是某个有资格加入该社团的患者的看护或亲属。(c) 是医疗专业人士（例如医生、护士、医学研究者等等），或者 (d) MIT 媒体实验室或 LTA 会员或雇员授权的客人。<br><br>\n\n禁止 13 岁以下儿童注册会员。注册成为会员则表明您已年满 13 岁或以上。<br><br>\n\nMIT 媒体实验室和 LTA 有权在任何时间更改或中止本网站任何特性，包括网站内容、有效时间以及访问或使用网站所需的设备。您已理解并同意只有在上述使用条款约束下才能使用本网站。MIT 媒体实验室和 LTA 保留在任何时间、以任何理由取消您帐户的权利——包括发现您提供虚假或误导性注册信息或违反使用条款。<br><br>\n\n**本网站不提供医疗建议**\n\n本网站提供的所有材料，包括文章、疗法、剂量、预后、图形、患者概况、图表、照片、图片、建议、信息、论坛发帖和任何其它资料都是用以获取信息，并不能替代专业的医疗建议或治疗。当您对自身健康存有疑问时，请及时咨询您的医生或其他有资质的医疗服务提供者。千万不要因为您在网站中看到的某些内容而忽视专业医疗建议或延误就医。<br><br>\n\n如果您认为自己可能得了急症，请立即联系您的医生或拨打 911。MIT 和 LTA 不推荐或认可本网站上可能提及的任何特定检查、医生、产品、疗程、观点或其它信息。如果您信赖由 MIT 或 LTA 、或由 MIT 或 LTA 邀请至本网站上的任何个人、或由其他会员提供的任何信息，则必须自己承担风险。<br><br>\n\n**会员如何合理合法地使用网站**\n\n会员不准在网站上发布或上传以下任何信息或其它内容：(a)虚假的、不准确的或误导性的信息；(b) 淫秽下流的信息；(c) 侵犯任何版权、专利、商标、商业机密或其它所有权或公共权益或任何组织和个人隐私权的信息；或 (d) 含有诋毁、诽谤、威胁、侮辱、仇恨或色情内容的信息。会员不能干扰其他会员使用和享受本网站。会员不得使用本网站从事任何非法或侵犯他人权利的活动，不得发送教唆非法活动的信息或鼓动针对任何组织或个人的人身损害或伤害。<br><br>\n\n所有会员都应认可并担保她们注册为会员时和随后提供的任何关于自身和其会员身份的信息都是真实、准确且非误导性的。<br><br>\n\n**会员与非会员使用网站**\n\n您不得以任何目的通过注册机、蜘蛛软件、自动抓取软件或其它自动化方法访问网站、获取其内容或获得其提供的服务。您不得向网站发送任何含有病毒、木马、蠕虫、定时炸弹、蜘蛛或其它故意损害、恶意干扰、秘密拦截或侵占系统、数据或个人信息的电脑程序的内容。不得通过拒绝服务攻击或类似手段使网站瘫痪。不得使用会员提供的联系方式或收集关于会员的信息以向其发送其不需要的信息（如 SPAM 或 SPIM 垃圾信息）或允许他人使用您的会员账号进行这些活动。<br><br>\n\n本网站的所有文章、图片、符号、标志、汇编（指对信息进行的收集、整理和汇总），包括任何“提交”（在下文中有其定义），以及通过邮件或其它方式发送给您的上述任何内容（统称为“网站内容”）均归 MIT、LTA 或第三方所有。应用于用户提交的健康数据的限制规定将在下面单独列出。<br><br>\n\nMIT 和 LTA 允许您在下列条件下查看、下载和打印网站内容：(a) 当您被要求评价网站上显示的物品和服务是否适合您的预期用途时，您只能数额有限地下载和打印网站内容；(b) 不得更改网站内容；(c) 任何显示出和打印出的网站内容必须标注“Copyright © 2008 MIT 媒体实验室（新媒体医疗）。保留所有权利。”；(d) 不得删除网站内容中已标注的任何版权、商标或其它所有权标识。除非得到明确的许可，在未经 LTA 预先书面许可时拷贝、修改后复制、再分发、再版、上传、发帖、传播、分销或以其它任何形式对网站内容或其某一部分的利用都是被严格禁止的。而且，在未经我们预先书面准许时不得链接网站或网站任何内容或框架，或通过其它任何形式将本网站内容显示在任何网站或其它位置上。<br><br>\n\n**会员的非商业性使用**\n\n会员专区和其中包含的内容及信息仅限会员个人使用，不得与任何商业行为挂钩。任何组织、公司和/或商业团体都不能成为本网站会员，且在未经 MIT 媒体实验室或 LTA 预先书面授权时不得使用本网站。<br><br>\n\n**隐私权**\n\n您已同意自己阅读、理解并接受了 MIT 媒体实验室为使用该网站设置的隐私政策（“隐私政策”）该政策监管所有选择使用本网站的用户（包括发送“提交”的用户）收集、使用和分享个人和非个人的信息。<br><br>\n\n**提交**\n\nMIT 媒体实验室和 LTA 欢迎您对本网站和网站内容作出评论。当您应 MIT 媒体实验室和 LTA 的要求或通过自身使用本网站向它们呈递意见、建议、资料或其它信息（上述所有行为都算作“提交”）时，这些“提交”将被视为、且将保持为 MIT 媒体实验室和 LTA 的专有财产。MIT、LTA 或其附属机构（将在下文中定义）不会把“提交”视为保密信息，也不会对使用或透露任何“提交”所带来的结果负责。在未作出上述限定的情况下，MIT 和 LTA 将永久共同拥有对所有“提交”的现在已知的和今后出现的权利，并有权不受限制地以任何合法目的——无论是商业目的还是其它目的，通过任何方式、任何媒介使用“提交”，且无需对“提交”的提供者、作者、创建者或发明者支付报酬（“参与者”）。任何参与者都要不可更改且无条件地放弃并保证不向 MIT 和 LTA 或其附属机构、雇员、部门、继任者、分派者、持证者或客户（统称“MIT 和 LTA 及其附属机构”）及本网站任何用户索取上述任何权利。<br><br>\n\n**在会员专区发帖和使用内容**\n\n会员专区包括多个社交区域，例如论坛和其他会员区域，在这里会员可以发布消息、图片和其它评论。如果您是一名会员，您（或作者）保留您在会员专区所发布的帖子、图片和其它内容的版权。但是，一旦您向会员专区发布这些内容，就视为您认同 MIT 媒体实验室、LTA 和它们各附属机构有权使用、拷贝、显示、演示、分销、翻译、编辑并在网站隐私政策限定范围内在您的帖子基础上创建衍生内容。<br><br>\n\n虽然会员专区中的部分社交区域要定期接受实事性话题监管，但 MIT 和 LTA 没有义务对帖子进行预过滤，也不对帖子的内容负责。我们鼓励您向我们举报网站中不当的和非法的内容，并且我们保留以任何原因删除帖子的权利。<br><br>\n\n您同意在未经网站会员书面准许之前不会将使用本网站所获得的一切个人身份性信息（无论是在会员专区发帖公布还是某一会员通过电子邮件发送给您）透露给任何个人或实体。您可以透露有关某个普遍事实的信息，但要保证这不会引起提供该信息的会员或与该信息相关的会员的身份暴露给上述非商业使用条款所限定的本网站之外的第三方。<br><br>\n\n**会员密码和登录身份**\n\n您有义务为自己的会员密码和登录身份保密，并且要对以自己的密码或账户所作出的一切您知道和不知道的行为负全责。如果您在知情时仍将自己的登录账户和密码透露给他人，您的会员特权将被暂停或终止。您同意在发现自己的会员密码或登录账户未经本人同意而被使用或发现其它任何安全性受到破坏的事件时立即通报 MIT 媒体实验室和 LTA 。<br><br>\n\n**健康数据**\n\n本网站鼓励您提交并分享关于您的健康和疾病史的数据。您对自己输入的任何健康数据拥有包括修改、删除、下载和分享等在内的特权。MIT 和 LTA 对您的数据的使用需要遵守隐私政策限制。您的个人数据将被本网站用于建立对于相关疾病患者族群的综合的、去识别化的认识。您同意不在网站的问卷或日志中输入个人身份识别性信息。只有用户首选项部分可以出现身份识别性信息。<br><br>\n\n健康数据不包含任何来自论坛的、被认为是公开性的且需要按照前文所述的提交类信息来管理的信息或评论。用户间可以通过互发电子邮件进行不公开的私人接触。<br><br>\n\n健康数据在未来网站发布综述时可以从其中删除，但您先前的数据仍将以存档的、去识别化的形式被保存。要在系统的可用部分中删除您的数据和身份性信息，请将您的指示通过电子邮件发送至 \nLAMsightHelp@lamtreatmentalliance.org.<br><br>\n\n**第三方网站的链接不被认可**\n\n本网站包含通向第三方网站的链接。这些链接的网站不在我们控制之内，我们对这些链接网站的内容也不负有责任。我们设置这些链接仅出于方便用户的目的，这些链接不代表 MIT 或 LTA 认可、赞助或附属于相关网站。商家或广告客户的链接属于独立的零售商或服务提供者并归其自行运营，因此我们对其产品、服务或商业行为不提供任何担保或代理。请您在与这些第三方团体进行任何交易之前慎重考虑和调查。<br><br>\n\n**会员资格终止**\n\n您同意 MIT 媒体实验室和 LTA 可能在有原因或无原因，且无事先通知的情况下立即终止您的会员资格和您进入会员专区的权利。在未限定上述条件情况下，终止会员资格的可能理由包括，但不仅限于下列内容：(a) 破坏或违反该协议或其它合并协议或政策，(b) 受到执法部门或政府机构要求，(c) 您主动提出要求（会员主动终止），(d) 不可预料的技术困难或故障，以及 (e) 在网站中闲置时间超限。MIT 和 LTA 没有义务保留、存储或向您传输您发送或上传到网站上的信息或数据。<br><br>\n\n**对该协议的修正**\n\n我们保留在任何时间且不经预先通知的情况下修改该协议书的权利，修改后的条款将通过发帖显示在网站上。我们鼓励您定期查看该协议书内容以了解其中的更新或修改，这些更改会通过协议书的修订日期体现出来。<br><br>\n\n**免责声明**\n\n本网站及其内容和其提供的服务都是建立在“现状”和“现有”的基础上。MIT 和 LTA 不承诺任何表述性的和暗示性的担保和代理，包括但不限于法律允许范围内的任何有关本网站、网站内容或网站提供的建议或服务所含特定目的之适当性的暗示担保。MIT 和 LTA 不担保访问网站或获取其内容或服务不会对他人产生干扰，或不会出错，或网站中的错误都会得到更正。<br><br>\n\n网站中其他成员通过发帖或电子邮件提供的意见、推荐、信息和结论并未以任何途径得到 MIT 媒体实验室或 LTA 的审查、认证或认可。您认可自己将对使用这些信息承担全部风险。<br><br>\n\n**责任限制**\n\nMIT、LTA 及其附属机构在任何情况下都不会对由于您使用该网站或信任该网站任何内容或服务而造成的间接的、偶然的、专属的或必然的损失负责。<br><br>\n\n**赔偿金**\n\n在由于自己违反该协议而招致或引起或被认为引起任何主张、行动或要求、损失、花费、责任和清算时，其中包括但不限于律师费和其它费用，您同意赔偿、保护且不损害 MIT、LTA 及其附属机构。<br><br>\n\n**国际用户**\n\nMIT 和 LTA 不担保在美国之外地区（“国际使用”）下载、存储或透露网站信息时仍能与用户所在地的法规和政策等相适应。提交给本网站的个人信息（“信息”）将按照现行的美国法律和我们的隐私政策来进行收集、处理、存储、公布和处理。如果您是国际用户，则您确认并同意 MIT 和 LTA 可能将收集和使用您的信息并将其透露给您所在地管辖范围之外的其它实体。并且，这些信息可能储存在您居住地管辖范围之外的服务器中。在向我们发送信息时，您已确认自己同意将这些信息传输到所在地管辖范围以外的地方，这在我们的隐私政策中已有详细说明。如果您不同意这种信息传输，您可能无法使用该网站。<br><br>\n\n**会员提示**\n\n如果您注册成为会员，则您同意 MIT 媒体实验室和 LTA 将通过电子邮件向您注册时提交的邮箱（或注册后通过网站功能而更换的新邮箱）发送提示信息。<br><br>\n\n**监管法律和地点**\n\n本协议受马萨诸塞州法律和现行美国联邦法律管辖。任何由本网站会员或使用本网站所产生的纠纷，都应在马萨诸塞州的萨福克县或米德尔塞克斯县的州立或联邦法院提起诉讼。<br><br>\n\n**数字千年版权法案**\n\n数字千年版权法案（17 U.S.C. §512 修订版）约束该网站的运营和维护。关于侵权提示的详细说明可参阅 [“麻省理工学院数字千年版权法案”页][1]。<br><br>\n\n**非弃权**\n\n当您不遵守或违反该协议规定的任一条款和条件时，MIT 或 LTA 将行使其相应权利，这一过程中任何延误或未执行都不会削弱这些权利，也不能理解为弃权；并且，MIT 或 LTA 对您执行的任何一项约定、条件或协议的弃权，不能理解为对任何后继损害的弃权或对任何其它约定、条件或协议的弃权。在该协议中，“包括”意为“包含但不仅限于。”<br><br>\n\n**合同终止**\n\n如果该协议中任何条款被某个有管辖权的法院认定为在任何现行或未来的法律之下无效、非法或不可执行，那么只要该协议规定范围内的各方权利和义务不受到本质上的或不良的影响，这些条款将被全部废止，同时该协议的其余条款将在法律允许的最大限度内继续保持其全部效力。除非另有明确规定，从其管辖对象来说，该协议阐明了您与 MIT 和 LTA 达成的全部协议，它将取代先前对于这些对象的所有书面或口头的承诺、协议或申述。您同意该协议的电子版可作为“书面”文件，而您在此对协议条款和条件的同意将作为对所有目的都生效的“签字”<br><br>\n\n**使用名称**\n\n未经 MIT 的技术认证办公室预先书面许可，本网站用户不得使用“MIT”、“麻省理工学院”、“MIT 媒体实验室”或任何与上述词汇相关的变异词、改编词或简称，或者其任何托管人、管理者、教职员、学生、雇员或代理的名称，或任何属于 MIT 的商标，或任何该协议中的条款，或任何促销性资料或公共启事或告示的名称。<br><br>\n\n“LTA” 标志和本网站使用的其它任何商标都属于 LTA 的资产，它们不得与任何非 LTA 提供的服务或产品挂钩，也不得以容易引起客户混淆的方式，或任何可能贬低、污蔑 LTA 名誉的方式出现。任何对这些标志和网站上显示的其它标志的使用，都只能单独保证其所有者的利益。<br><br>\n\n其它所有出现在 LAMsight 网页上的商标名和标志都属于第三方团体。<br><br>\n\n网站中使用的所有软件都是我们或第三方团体的资产，除非要求进行前面所述的认证，任何将这些软件再分配、销售、反编译、逆向工程、拆解、翻译或其它将软件还原为人类可读形式的行为都是被禁止的。<br><br>\n\n您同意、表示并担保自己对本网站及其内容或其中任何一部分的使用都将遵守上述条款、约定和限制，并绝不会侵犯或违背任何其它团体的权利，或者破坏任何与其它团体订立的合同或法律责任。并且，您同意自己会遵守所有与本网站及其内容，或您对其使用有关的现行法律法规（“法律”），且您将对违反相关法律条款承担全部责任。<br><br>\n\n**转让**\n\nMIT 或 LTA 有权在任何时间将该协议作为新合并企业的一部分或全部资产销售的一部分来转让给其子公司、母公司或业务继任者。您不得转让或转移该协议。<br><br>\n\n如果您对我们的使用条款存有疑问或意见，请通过以下方式联系我们：LAMsightHelp@lamtreatmentalliance.org。您也可以将对该协议的提问、评论或反对意见直接提交到：<br><br>\n\nMIT Media Laboratory <br>\nE15-401 c/o Frank Moss <br>\n20 Ames Street <br>\nCambridge, MA 02139<br>\nUSA<br>\n\n\n  [1]:http://web.mit.edu/ist/topics/security/copyright/filing-notice.html “MIT 的 数字千年版权法案页面”"

# ARTICLE TITLE
#: 22816 TITLE
msgid "Privacy Policy"
msgstr "隐私政策"

# ARTICLE CONTENT
#: 22816 CONTENT
msgid "**Effective December 11th, 2008**<br><br>\n\nLAMsight acknowledges that our website, www.lamsight.org (the “Site”), can only provide the Community with an effective tool if we build trust among patients/ members. This privacy policy (the “Policy” or “Privacy Policy”) outlines the type of information LAMsight collects from our members and how it is shared with other parties. We reserve the right to modify this policy at any time, and without prior notice, by posting amended terms on this website. We encourage you to review this policy periodically for any updates.<br><br>\n\n**WHAT KIND OF DATA WE COLLECT AND WHY**<br><br>\n\nLAMsight enables patients to provide information about their disease history, family history and lifestyle online so that the collective knowledge of thousands of patients can be shared with others affected by the disease, as well as researchers. Our collective success in achieving this goal depends on LAM patients’ willingness to share their data with researchers so they can work more effectively to find a treatment for LAM.<br><br>\n\nThe type of data patients may add to their profiles ("Profile Data") \nmay include:\n\n\n  - Condition/disease information,\n    including diagnosis date,\n    first symptom information, and\n    family history\n  - Treatment regimens, including\n    treatment start dates, stop dates,\n    and dosages\n  - Symptoms experienced, including\n    severity and duration <li>Primary\n    and secondary outcome scores (e.g.\n    FEV1, DLCO,  FVC, weight and so on)\n    over time\n  - Biographical information, including\n    age, location (city, state &\n    country), and general notes.\n\n\nPatients may voluntarily enter information that identifies them ("Personally Identifiable Information” such as name, address, email, and birth date) into their Profile Data. LAMsight will hold Profile Data and personally identifiable information provided by patients in the strictest confidence and maintain the security of such information in accordance with all applicable laws. Such data will only be available to the site manager and will not be released to any parties in any form that will identify the patient, without the patient’s prior written authorization. You will be asked for an email address and to make a selection of preferences about how your personal information can be used to contact you for administrative and research purposes. For example, you can authorize researchers to contact you with information about drug trials or requests for further information (if, for example, they want to test a new hypothesis about LAM).<br><br>\n\nThe site allows patients and researchers to make their own surveys and requests for data.  Data entered into any survey in the Collect section of the website is available to the rest of the community in aggregate form as described above.  You should never enter Personally Identifiable Information into any of these forms if you are concerned about privacy.  Please comment on any forms that you feel violate common sense protection of privacy.<br><br>\n\nWe may periodically ask you to complete short surveys about the site itself. Your participation in these surveys is not required, and your refusal to do so will not impact your experience on the website. Our aim is to create the best possible tool for research, as well as provide global information for patients. We would appreciate any input on site surveys etc. that you are willing to provide.<br><br>\n\nCookies are required to use the LAMsight service. A cookie is a small data file, which often includes an anonymous unique identifier that is sent to your browser from a web site's computers and stored on your computer's hard drive. LAMsight uses two types of cookies: Session Cookies, and Persistent Cookies. Session Cookies are temporary cookies that remain in the cookie file of your browser until you leave the Website. Session cookies do no store any personally identifying information, only a unique visitor ID number that we can use to customize the LAMsight functionality for you. Persistent Cookies remain in the cookie file of your browser for much longer, even after you leave the LAMsight website. Persistent cookies do no store any personally identifying information, only preferences that should persist from visit to visit, like "Remember Me".<br><br>\n\n**HOW YOUR PERSONALLY IDENTIFIABLE DATA IS USED**<br><br>\n\nIn order to help researchers and to learn from our collective experiences of LAM, your Survey and Diary Data will be aggregated and made available to other members in aggregate non-identifiable form. For example, we may report the number of patients trying a particular treatment or the number of patients experiencing a particular symptom.  This aggregate data will not include your personal information.<br><br>\n\nBy completing your Profile Data, your personal information will be added to our database, which will be used for research purposes only. For example, we may look at scientific questions such as, "Do certain experimental treatments seem associated with certain sub-populations of patients?" At LAMsight and in conjunction with external researchers, we’re interested in better understanding the experience of living with chronic conditions like LAM and improving treatment options and health outcomes for everyone, including people with LAM.<br><br>\n\nLAMsight will not rent, sell or share information that \npersonally identifies you for marketing purposes.  We may subsequently assign control of LAMsight and all of its rights and obligations to another entity, to ensure its continued availability and use.  You will receive timely notice of such an assignment, and have the option of deleting your personal information prior to such a transfer.<br><br>\n\nLAMsight’s goal is to allow researchers direct and anonymous communication with you through our system. Furthermore, we may also provide researchers with anonymized data (which may or may not be aggregated) for research purposes only. Personal identifiers will be used only to contact and to de-duplicate information and will not be available to anyone without your explicit permission.<br><br>\n\n**OTHER SECURITY ISSUES**<br><br>\n\nLAMsight will take reasonable measures to safeguard your personal information and identity from any other members with whom you may interact in the course of using the Site or who may have access to information you have posted in the Discuss area. Researchers requesting access to the data on LAMsight will be personally vetted by MIT or selected affiliates such as the LAM Treatment Alliance or the LAM Foundation.<br><br>\n\nAt some point we may choose to implement a method by which we can increase confidence in the identity of a user of LAMsight (a researcher, a patient, a family member, etc.).  This method will involve trusted individuals providing a reference for another individual.  We and our partners may also take the extra step of directly identifying researchers and limiting access to any researchers who have not gone through this process.<br><br>\n\n**RISKS AND BENEFITS**<br><br>\n\nLAM is a rare disease with a small global population. Our goal is to facilitate the interaction between patients and researchers by providing medical and lifestyle information, which will enable researchers to test hypotheses, study risk factors previously unknown and to contact patients with information about drug trials, new treatments or request additional information. A key objective in providing the LAMsight platform is to improve health outcomes and expedite the development of a successful treatment and cure for LAM. Although there are no certain benefits to using this Site, by pooling information and resources and encouraging more researchers to initiate and develop an interest in LAM, we hope that LAMsight will foster the necessary access to otherwise un-captured global patient data that can accelerate the pace of LAM research.<br><br>\n\nUsers may elect to stop using this Site at any time. You are free to skip any questions or data fields that make you feel uncomfortable. You will have full control over your information, including the ability to download, remove all personal identifiers, or to remove data from the system subject to the conditions described below.<br><br>\n\n**QUESTIONS ABOUT THE PRIVACY POLICY**<br><br>\n\nIf you have questions or comments about our Privacy Policy, please contact us at: LAMsightHelp@lamtreatmentalliance.org. You can also direct questions or comments to: <br><br>\n\nLAMsight<br>\nMIT Media Laboratory<br>\n20 Ames Street, E15-401 c/o Frank Moss<br>\nCambridge, MA 02139<br>\nUSA<br>"
msgstr "**2008 年 12 月 11 日生效**<br><br>\n\nLAMsight 确认我们的网站 www.lamsight.org （“本网站”）只有在患者/会员间建立广泛信任基础上，才会为我们的社团提供更有效的工具。该隐私政策（“政策”或“隐私政策”）列出了 LAMsight 从我们的会员中收集的信息类型以及这些信息如何被分享给其它团体。我们保留在任何时间、且不作出预先通知的情况下修正该隐私政策的权利，修正后的政策条款将通过帖子发布到本网站上。我们鼓励您定期查看该协议内容以了解其中的更新。<br><br>\n\n**我们收集何种信息？为什么收集？**<br><br>\n\nLAMsight 使得患者能够在线提供有关她们的病史、家庭病史和生活方式方面的信息，从而使来自数千名患者的知识得以分享给其它受该病困扰的患者和研究者。我们实现这一收集目标的成功取决于 LAM 患者们将其数据分享给研究者的意愿，以便她们能更有效地找到治疗 LAM 的方法。<br><br>\n\n患者可向其概况（“概况数据”）中添加的数据类型 \n可能包括：\n\n\n- 病情/疾病信息\n    包括诊断日期\n    首发症状信息，以及\n    家庭病史\n  - 治疗方案，包括\n    治疗起止日期，\n    用药剂量\n  - 出现症状，包括\n    严重程度和持续时间 <li>首要\n    和次要预后评分（例如\nFEV1、DLCO、FVC、体重等等）\n    结束时间\n  - 自传信息，包括\n    年龄、居住地（城市、州和\n    国家），以及常用信息。\n\n\n患者可以自愿地将其身份性信息（“个人身份性信息”如姓名、住址、电子邮箱、出生日期等）填写到其概况数据之中。LAMsight 将对患者提供的文件数据和个人身份性信息进行严格保密，并将遵照所有现行法律保持这些信息的安全性。这些数据只能被网站管理者获取，且不会在未经患者书面授权的情况下以任何可能暴露患者身份的形式泄露给任何团体。在注册进入网站时您需要提供一个电子邮箱地址并选择用户首选项，以决定我们由于管理或研究目的而联系您时如何使用您的个人信息。例如，您可以授权研究者和您联系以获取药物试验的信息或更多信息（比如，他们要试验一种关于 LAM 的新假说）。<br><br>\n\n本网站允许患者和研究者创建自己的调查和数据请求。在网站“收集”部分输入问卷的任何数据都可以通过上文所描述的集中表格分享给社团内其他成员。如果您担心隐私权受到损害，那么切勿在这些表格中填入任何个人身份性信息。如果您认为本网站中任何表格违反了隐私权的保护常识，请及时提出批评意见。<br><br>\n\n我们会定期请您填写关于网站本身的简短调查问卷。我们并不强制要求您参与此类调查，如果您拒绝也不会对您在本网站的任何体验造成影响。我们的目的是为患者创造最佳的搜索工具，同时提供全球性的信息。我们非常感谢您填写网站调查问卷和提供其它任何您愿意提供的信息。<br><br>\n\n使用 LAMsight 服务需要 Cookies。cookie 是一个小型数据文件，通常包含一个匿名的唯一标识，该标识由某网站电脑发送到您的浏览器上，并存储在您电脑硬盘中。LAMsight 使用两种类型的 cookies：Session Cookies 和 Persistent Cookies。Session Cookies 是在您离开网站之前暂存于浏览器的 cookie 文件夹中的暂时性 cookies。Session cookies 不存储任何个人身份性信息，只包含一个独有的访问者 ID 号码，我们可用它来为您订制 LAMsight 功能。Persistent Cookies 在您浏览器的 cookie 文件夹中保存的时间则要长得多，即使在您离开 LAMsight 网站后也不消失。Persistent cookies 不存储任何个人身份性信息，只在多次访问之间保存用户首选项，就像“记住我”的提示。<br><br>\n\n**您的个人身份性数据将如何被使用**<br><br>\n\n为了帮助研究者并且从我们积累的关于 LAM 的经验中学到更多东西，您的问卷和日志数据将被集中并以非身份性合计表格的形式提供给其他会员。例如，我们会报告接受某一特定疗法试验的患者人数，或者出现某一特定症状的患者人数。该合计数据不会包含您的个人信息。<br><br>\n\n通过完成概况数据，您的个人信息将被加入我们的数据库，该库仅供研究目的使用。例如，我们会研究一些学术问题，如“某项试验性疗法是否与某一患者亚群相关？”无论在 LAMsight 还是与外界研究者合作，我们最关注的都是更好地理解 LAM 之类慢性病患者的生活感受，并改善包括 LAM 患者在内每个人的疗法和健康预后。<br><br>\n\nLAMsight 不会因营销目的出租、出售或分享 \n可能暴露您个人身份的信息。我们随后可能会将 LAMsight 的控制权以及其所有权利和义务转让给其它实体，以保证其持续的有效性和实用性。您会及时收到关于此类转让的通知，也可以选择在此类转让前删除您的个人信息。<br><br>\n\nLAMsight 的目标是让研究者直接地和匿名地通过我们的系统和您交流。更重要的是，我们还将为研究者提供匿名的数据（可能是合计的或非合计的），这些数据仅供研究目的使用。个人身份性信息仅用于联系您和保证信息不重复，在未经您明确许可前不会透露给任何人。<br><br>\n\n**其它安全问题**<br><br>\n\nLAMsight 将采用合理的手段以保护您的个人信息和身份不被任何可能在使用网站过程中与您接触的会员或任何可能获取您在讨论区发帖信息的成员知晓。申请在 LAMsight 上获取数据的研究者将以个人身份接受 MIT 或其选定的附属机构的审查，例如 LAM 治疗联盟或 LAM 基金会。<br><br>\n\n在某些时候我们可能采用某种方法来增加对某一 LAMsight 用户的身份的保密程度（研究者、患者、患者家属等等）。该方法中包括由一名可信的成员推荐另一名成员。我们和我们的合作伙伴也会再添加一步骤，即直接识别确认研究者，并限制接触未通过该步骤审核的研究者。<br><br>\n\n**风险和效益**<br><br>\n\nLAM 是一种罕见病，全球患者数量也较少。我们的目标是通过提供医疗和生活方式信息来促进患者与研究者间的互动，这将使研究者有机会验证其设想、研究未知风险因素并与患者交流药物试验、新疗法或其它所需信息。建立 LAMsight 平台的一大关键目的是改善 LAM 的健康预后并推动针对该病的成功疗法和药物快速发展。虽然使用该网站不会带来必然效益，但通过汇集信息和资源并鼓励更多研究者产生和培养对 LAM 研究的兴趣，我们希望 LAMsight 能够将原本无法捉摸的全球 LAM 患者数据整合为可稳定获取的数据源，从而加快 LAM 研究的步伐。<br><br>\n\n用户可选择在任何时间停止使用本网站。您可以自由跳过任何使您感到不适的提问或数据区域。您将对自己的信息拥有全部的控制权，包括下载、删除所有个人身份性信息，或在下述情况中将数据从系统中删除。<br><br>\n\n**关于隐私政策的问题**<br><br>\n\n如果你对我们的隐私政策存在疑问或意见，请通过以下方式联系我们：LAMsightHelp@lamtreatmentalliance.org。您也可以将提问或意见直接提交至：<br><br>\n\nLAMsight<br>\nMIT Media Laboratory<br>\n20 Ames Street, E15-401 c/o Frank Moss<br>\nCambridge, MA 02139<br>\nUSA<br>"

# ARTICLE TITLE
#: 24610 TITLE
msgid "Public Page Header"
msgstr "公共主页标题"

# ARTICLE CONTENT
#: 24610 CONTENT
msgid "A community dedicated to fast-tracking LAM research.\n========================================\n\nLAMsight enables LAM patients to contribute to research in a new and easy way and gives LAM researchers real-time ongoing access to critical data from the global LAM patient population.<br><br>\n\n[*What is LAM?*][1]\n\n\n  [1]: http://lamtreatmentalliance.org/understand_overview.html "What is LAM?""
msgstr "一个致力于推进 LAM 研究快速发展的团体。\n========================================\n\n借助 LAMsight，LAM 患者可以通过一种新颖而简易的途径支持医学研究，而 LAM 研究者则可以不断地实时获得来自全球 LAM 患者族群的重要数据。<br><br>\n\n[*什么是 LAM?*][1]\n\n\n  [1]：http://lamtreatmentalliance.org/understand_overview.html “什么是 LAM?”"

# ARTICLE TITLE
#: 24611 TITLE
msgid "Home Page middle"
msgstr "主页中部"

# ARTICLE CONTENT
#: 24611 CONTENT
msgid "The LAMsight web portal is a collaboration between the LAM Treatment Alliance (LTA) and the Massachusetts Institute of Technology (MIT). It is a purely not-for-profit project intended to foster collaboration, impact and data access among all members of the LAM community – patients, researchers, and clinicians. [Click here to read more about LAMsight.][1]<br><br>\n\n**If you are a patient,** you can use LAMsight to share your knowledge anonymously and learn from other patients around the world. LAMsight enables you to contribute to research happening now and makes it possible for you to be contacted if you qualify for future clinical trials.<br><br>\n\n**If you are a patient, researcher, or clinician,** you can access and shape a central database of information built collaboratively by LAM patients and researchers around the world, across languages, nationalities, and country-based organizations in order to increase the speed and impact of LAM research focused on treatment and cure.<br><br>\n\nWe are grateful to the many pilot testers from the global LAM community who have provided crucial feedback for this final beta-testing phase of LAMsight.<br><br>\n\nJoin us in keeping our eye on the prize: treatment and cure within the lifetime of patients now living with LAM. If you are a patient, patient family member, researcher or clinician, please register now, and send us your critical feedback. Our collective effort helps to accelerate progress in life-saving LAM research.<br><br>\n\n\n  [1]: /about "Click here to read more about LAMsight.""
msgstr "LAMsight 门户网是由 LAM 治疗联盟 (LTA) 与 麻省理工学院 (MIT) 联合创办。它是纯粹的非营利性网站，旨在促进 LAM 社团所有成员——患者、研究者和医生之间的协作、互助和数据共享。[单击此处以了解更多关于 LAMsight 的情况。][1]<br><br>\n\n**如果您是一名患者，** 您可以通过 LAMsight 以匿名方式与他人分享您的知识，还可以从全球的其他患者那里学到更多知识。通过 LAMsight，您不仅能支持现有的医学研究，还能联系相关研究者以确认自己是否有资格参与未来的临床试验。<br><br>\n\n**如果您是一名患者、研究者或医生，** 您可以访问并构建由全球的 LAM 患者和研究者共同建立的信息中央数据库，通过多语言、多国家和多个国家级组织来加快和加强 LAM 专注于药物和疗法的相关研究。<br><br>\n\n我们非常感谢那些为 LAMsight 网最终的 beta 测试阶段提供重要反馈信息的全球 LAM 社团中的测试者们。<br><br>\n\n您的加入将帮助我们早日实现梦寐以求的目标：为全球的 LAM 患者在其有生之年找到理想的药物和疗法。如果您是 LAM 患者、患者家属、研究者或医生，请现在就注册，并您的重要反馈信息发送给我们。我们的数据收集工作将大大加快拯救生命的 LAM 研究进程。<br><br>\n\n\n  [1]：/关于“单击此处以了解更多关于 LAMsight 的情况。”"

# ARTICLE TITLE
#: 24702 TITLE
msgid "Public Home Bottom - Hormones"
msgstr "公共主页底部 - 激素"

# ARTICLE CONTENT
#: 24702 CONTENT
msgid "Hormones and Pulmonary Function\n===============================\n\nPatients have reported that their breathing appears to vary over the month, in some cases correlated with their menstrual cycle.  Researchers believe that evidence of a correlation between either estrogen or progesterone levels and performance on pulmonary function tests could provide important insights into LAM.<br><br>"
msgstr "激素和肺功能\n===============================\n\n据 LAM 患者反映，其呼吸状况会在每个月中出现变化，在某些个案中这一变化过程有时是与患者的月经周期相协同的。研究者相信，雌激素或黄体酮水平与肺功能测试中所体现出来相协同的现象将对认识 LAM 的本质有重要帮助。<br><br>"

# ARTICLE TITLE
#: 24703 TITLE
msgid "Public Home Less Commonly Discussed Symp"
msgstr "公共主页中较少讨论的症状"

# ARTICLE CONTENT
#: 24703 CONTENT
msgid "Less Commonly Discussed Symptoms\n================================\n\nFor various reasons, women with LAM often do not disclose all aspects of their experience living with the disease to their clinicians. We are interested in creating a place for researchers and clinicians to learn about these less commonly discussed symptoms and experiences.<br><br>"
msgstr "较少讨论的症状\n================================\n\n由于种种原因，LAM 女性患者往往不会向她们的医生透露其所有病情。我们希望为研究者和医生提供了解这些不常被提及的症状和经验的平台。<br><br>"

# ARTICLE TITLE
#: 24704 TITLE
msgid "Public Home Osteo"
msgstr "公共主页 － 骨科"

# ARTICLE CONTENT
#: 24704 CONTENT
msgid "Bone Dysfunction and LAM\n========================\n\nLAM cells exhibit features similar to cells involved in bone resorption, therefore scientists are interested in gaining more insight to a possible relationship between LAM, bone conditions and lung destruction. We'd like to collect additional information about your experience of bone loss to complement ongoing basic research on the molecular and mechanistic aspects of this question.<br><br>"
msgstr "骨功能障碍与 LAM\n========================\n\nLAM 细胞表现出与骨再吸收中相关细胞相似的特征，因此科学家们热衷于深入认识 LAM 与骨科疾病和肺损伤之间可能存在的关系。我们希望收集更多的关于患者骨流失症状的信息，以支持对这一问题的分子基础和发病机制进行的基础研究。"

# ARTICLE TITLE
#: 24705 TITLE
msgid "New Home Page"
msgstr "新主页"

# ARTICLE CONTENT
#: 24705 CONTENT
msgid "Welcome to the LAMsight community!\n----------------------------------\n\nResearchers and clinicians often remark that “there are too few patients” and thus, we know too little about LAM, research moves too slowly and clinical trials take far too long. This is the chance for patients around the world to come together to directly contribute to giving insight to researchers and clinicians about LAM. This is your chance to ensure that as new clinical trials begin, you will be contacted if you qualify, no matter where you live in the world. Your help makes progress in LAM research possible!<br><br>\n\nJust two more steps to get started. <br><br>\n\nYou can complete both steps now – they will take approximately 90 minutes total – or, come back and work on them later. At any point, you can save your data and continue with data entry during another visit.<br><br>\n\n**Step 1.** Start by completing your preferences to let us know (confidentially) who you are and how we can best communicate (approximately 5 minutes).<br><br>\n\n**Step 2.** Next, fill out these four surveys to record some basic facts about your experience with LAM (approximately 20 minutes each):\n\n  - [LAM Diagnosis][1]\n  - [General Medical History][2]\n  - [Behavior and Environment][3]\n  - [Reproductive Health][4]\n\n\n\nIn addition, we have three \n**featured studies** \nthat address timely issues of importance to the LAM research and patient communities. Please visit these pages to answer these important questions:\n\n  - [Hormones and pulmonary function][5] Patients\n    have reported that their breathing\n    appears to vary over the month, in\n    some cases potentially associated\n    with their menstrual cycle.  We are\n    doing a formal study within LAMsight\n    to gather high-density prospective\n    information on this relationship\n    using a low-cost home spirometer and\n    thermometer along with survey\n    questions.\n  - [Bone dysfunction and LAM][6] “LAM\n    cells” may exhibit features similar\n    to cells involved in bone\n    resorption.  Scientists are\n    interested in gaining more insight\n    to a possible relationship between\n    LAM, bone conditions and lung\n    destruction.  We'd like to collect\n    additional information about your\n    experience of bone loss to\n    complement ongoing basic research on\n    the molecular and mechanistic\n    aspects of this question.\n  - [Less commonly discussed symptoms -\n    incontinence][7] For various\n    reasons, women with LAM often do not\n    disclose all aspects of their\n    experience living with the Disease\n    to their clinicians. We are\n    interested in creating a place for\n    researchers and clinicians to learn\n    about these less commonly discussed\n    symptoms and experiences. Note that\n    not all women with LAM experience\n    the same symptoms. We are grateful\n    for your candid and confidential\n    participation in this and other\n    surveys. Please remember to comment\n    with any thoughts or additional\n    questions that you think would be\n    helpful to add to the existing\n    survey.\n\n\n\nThank you for your participation!\n\nMain Ways to Interact with LAMsight\n-----------------------------------\n\nYou now have four ways to interact with LAMsight, all focused on helping you to share information about your Disease and helping researchers and other members of the LAM community to learn more at a faster speed.\n\n 1. [Collect][8] *The heart of\n    LAMsight.* Here you can report\n    the physical and lifestyle issues\n    you experience living with LAM.\n    Easy-to-use interactive surveys\n    cover a wide range of topics,\n    including medicines (including\n    complementary and alternative\n    therapies), diet, exercise and\n    fitness, environment and other\n    factors.\n 2. [Explore][9] *Ask LAMsight a\n    question.* In the Explore\n    section, you can access aggregate\n    data compiled from questions\n    answered by patients around the\n    globe. Results summarize the content\n    and responses collected from\n    participants on any given question\n    or topic.\n 3. [Discuss][10] *Connect and\n    share.* Visit this section to\n    discuss surveys, ask questions, and\n    share observations. Discussions are\n    organized around key topics, such as\n    “How to Use LAMsight” and “Feature\n    Requests.” Contribute to existing\n    discussions and create new forum\n    topics.\n 4. [Create][11] *Add to the\n    knowledge base.* As you uncover\n    new aspects of your experience with\n    LAM that may be interesting to\n    researchers, and as new questions\n    for patients emerge for researchers,\n    use the Survey Editor to build new\n    surveys for the community. As\n    questions and surveys evolve,\n    previously overlooked aspects of the\n    disease may emerge, giving\n    researchers valuable clues and\n    insights into LAM and how to slow\n    and stop progression.\n\n<br>\n\nAs you use LAMsight, please \n[let us know][12] \nif you see ways that we can make improvements to better serve you in our collective effort to fast-track LAM research. <br><br>\n\nThe LAMsight Administrators<br><br>\n\n*LAMsight is a collaboration of the New Media Medicine group of the MIT Media Lab and the LAM Treatment Alliance.*<br><br>\n\n\n  [1]: /dashboard/collect/survey/6136 "LAM Diagnosis"\n  [2]: /dashboard/collect/survey/6121 "General Medical History"\n  [3]: /dashboard/collect/survey/5988 "Behavior and Environment"\n  [4]: /dashboard/collect/survey/6072 "Reproductive Health"\n  [5]: /dashboard/collect/survey/25604 "Hormones and pulmonary function"\n  [6]: /dashboard/collect/survey/24815 "Bone dysfunction and LAM"\n  [7]: /dashboard/collect/survey/24511 "Less commonly discussed symptoms - incontinence"\n  [8]: /dashboard/collect "Collect"\n  [9]: /dashboard/explore "Explore"\n  [10]: /dashboard/discuss "Discuss"\n  [11]: /dashboard/create "Create"\n  [12]: mailto:LAMsightHelp@lamtreatmentalliance.org "let us know""
msgstr "欢迎来到 LAMsight 社区！\n----------------------------------\n\n研究者和医生经常感叹“病人太少了”，因此我们对 LAM 仍知之甚少，医学研究进展缓慢，临床试验更是遥遥无期。此刻，全世界的 LAM 患者有机会走到一起，直接帮助医生和研究者更深入地认识 LAM 这一顽疾。无论患者身在世界何处，只要其符合临床试验的要求，就可确保在一项新的临床试验开始时能够与该患者联系。您的帮助是 LAM 研究前进的动力！<br><br>\n\n只需再完成两步即可开始。<br><br>\n\n现在您就可以完成这两步 – 这大概需要 90 分钟，或者您可以稍后再完成它们。在任何一步中，您都可以保存自己的数据并在下次访问时再继续填写数据。<br><br>\n\n**第 1 步** 从填写您的用户首选项开始，让我们（秘密地）了解您的身份以及我们如何能最好地交流（约 5 分钟）。<br><br>\n\n**第 2 步** 接下来，请填写四份调查问卷以记录您患上 LAM 后的基本情况（每份问卷约 20 分钟）。\n\n- [LAM 诊断][1]\n  - [总体病史][2]\n  - [生活习惯和环境因素][3]\n  - [生殖健康][4]\n\n\n\n此外，我们还有三项 \n**特征研究** \n用于及时将一些重要情况反映给 LAM 研究者和患者的社团。请访问以下页面来回答这些重要问题：\n\n- [激素和肺功能][5] 据 LAM 患者 \n  反映，其呼吸状况\n    会在每个月中出现变化，在\n    某些个案中这一变化过程很可能是与患者的\n    月经周期相协同的。 我们\n    正通过 LAMsight 网进行一项正式研究\n    以收集较为集中的\n    关于这种协同关系的预期信息，\n    其间我们将使用廉价的家用肺活量计\n    和体温计\n    进行问卷调查。\n- [骨功能障碍与 LAM][6] “LAM\n    细胞”表现出与\n    骨再吸收中相关细胞\n    相似的特征。因此科学家们\n    热衷于深入认识\n    可能存在的\n    LAM 与骨科疾病和肺\n    损伤之间的关系。我们希望收集\n    更多的关于患者\n    骨流失症状的信息，\n    以支持对这一问题的\n    分子基础和发病机制\n    进行的基础研究。\n- [较少讨论的症状 -\n    失禁][7] 出于种种\n    原因， LAM 女性患者往往不会\n    将其所有\n    病情\n    透露给她们的医生。我们希望\n    为研究者和医生\n    提供一个平台，以了解这些\n    不常被提及的\n    症状和经验。应当注意到，\n    不是所有 LAM 女性患者都出现\n    相同症状。我们衷心感谢\n    您参与此项和其它\n    问卷调查时的\n    坦白与信任。请提出\n     任何您认为\n    有助于现有调查问卷的\n    想法或更多问题\n    。\n\n\n\n感谢您的参与！\n\n与 LAMsight 互动的主要途径\n-----------------------------------\n\n现在您可以通过四种途径与 LAMsight 互动交流，这都是为了方便您分享自己的疾病信息并帮助研究者和 LAM 社团内其他成员更快地掌握更多信息。\n\n1. [收集][8] *LAMsight\n    的核心。* 您可以在此报告\n    您患 LAM 时经历的\n    身体和生活方式问题。\n简便易用的互动式问卷\n    它涉及广泛的话题，\n    包括医药（含\n    补充和替代\n    治疗）、饮食、锻炼和\n    健身、环境以及其它\n    因素。\n2. [探索][9] *向 LAMsight 提出\n    问题。* 在探索\n    部分，您可以获取\n    从全球患者回答的\n    提问中整理出的\n    集中数据。这些数据总结了\n    收集自\n    调查参与者回答的任意问题或话题的\n    内容和看法。\n3. [讨论][10] *联系和\n    分享。* 在这一部分，您可以\n    讨论问卷、提出问题和\n    分享观点。讨论是\n    围绕关键话题展开的，例如\n    “如何使用 LAMsight”和“功能\n    申请”。您可以参与现有\n    讨论并创建新的论坛\n    主题。\n4. [创建][11] *添加至\n    知识库。* 当您公开\n    未曾报道过的、\n    且可能是研究者很关注的\n     您的 LAM 病情的新特性时，当关于患者的新问题\n    涌现在研究者面前时，\n    请用问卷编辑器为 LAM 社团创建新的\n    调查问卷。随着\n    问题和问卷的不断发展更新，\n    先前被忽视的\n    一些疾病特性将被显露出来，这可以给\n    研究者提供关于 LAM 的有价值线索和\n    深入认识以及对如何延缓\n    乃至遏止该病发展的启示。\n\n<br>\n\n当您使用 LAMsight 时，请 \n[告诉我们][12] \n您是否认为我们在携手快速推进 LAM 研究的过程中有机会更好地为您服务。<br><br>\n\nLAMsight 管理者<br><br>\n\n*LAMsight 是由隶属于 MIT 媒体实验室的新媒体医疗小组和 LAM 治疗联盟协作创办的。*<br><br>\n\n\n  [1]：/dashboard/collect/survey/6136 “LAM 诊断”\n  [2]：/dashboard/collect/survey/6121 “总体病史”\n  [3]：/dashboard/collect/survey/5988 “生活习惯与环境因素”\n  [4]：/dashboard/collect/survey/6072 “生殖健康”\n  [5]：/dashboard/collect/survey/25604 “激素与肺功能”\n  [6]：/dashboard/collect/survey/24815 “骨功能障碍与 LAM”\n  [7]：/dashboard/collect/survey/24511 “较少讨论的症状 — 失禁”\n  [8]：/dashboard/collect “收集”\n  [9]：/dashboard/collect “探索”\n  [10]：/dashboard/collect “讨论”\n  [11]：/dashboard/collect “创建”\n  [12]：将电子邮件发至：LAMsightHelp@lamtreatmentalliance.org “告诉我们”"

# ARTICLE TITLE
#: 25302 TITLE
msgid "Collect: Help and FAQ"
msgstr "收集：帮助和常见问题"

# ARTICLE CONTENT
#: 25302 CONTENT
msgid "How to Use Collect\n------------------\n\nThe “Collect” section of the site enables the capturing of information. This is at the heart of the LAMsight’s core mission – to aggregate disease information about the global LAM patient population in a way that enables researchers to generate new insights about the disease and how to treat it based on a larger number of patient experiences  Data collection can take place as research questions arise and as the importance of certain symptoms, for example, becomes more clear. The information provided will be used by patients and researchers in their collaborative efforts to better understand the causes of LAM and how to slow and stop it.<br><br>\n\nThis section consists of interactive surveys that adapt to the answers that you provide as you progress through the questions. Because we are continuously striving to improve these surveys, we ask that you click on the comment icon next to each question in order to provide us with feedback about questions. Please let us know if they are clear, useful, interesting, etc.<br><br>\n\nFrequently Asked Questions\n--------------------------\n\n**How do I start?**<br><br>\n\nAfter filling out your Preferences, please proceed and complete the following four priority surveys:\n\n  - [Original LAM Diagnosis][1]\n  - [Existing Medical Information][2]\n  - [Behavior and Environment][3]\n  - [Reproductive History][4]\n\n**How long does it take to complete each survey?**<br><br>\n\nThe length of time it takes to complete a question varies by person and by questionnaire.  You can see a list of pages on the right of the screen that helps you to track your progress (i.e. what you have completed and how much of the survey is left for you to answer). We aim to keep questionnaire pages to one or two screens. We try to hide information that is not relevant to you.  You can safely move forward and back through the questionnaire using the “Next” and “Previous” buttons at the top of the page. You can also leave the survey and return at any time and your work will be saved.<br><br>\n\n**Can I save my information and return later to complete a survey?**<br><br>\n\nYes. At the end of each question, you will have three options:  \n\n  - “Continue to Next Question,”\n  - “Save and Finish Later,” and\n  - “Clear Answer.”\n\n**Can I change my answers to a completed survey?**<br><br>\n\nYes, you can come back and change your answer at any time.  We do keep a confidential history of prior answers to ensure the integrity of the data, but the data that the site produces when people use the Explore section of LAMsight will reflect your most recently updated answer.<br><br>\n\n**Do I have to complete every survey?**<br><br>\n\nNo.<br><br>\n\n**Who has access to the completed surveys?**<br><br>\n\nYour personal information is available only to you and to the MIT site administrators for technical purposes and not for release to any third party. Your data are visible only in an aggregated (i.e. collective) form in the Explore interface and in a de-identified (i.e. no personal details) form to researchers. See our Privacy Policy for more detail.<br><br>\n\n**I have an idea for a survey. Can I submit one?**<br><br>\n\nAbsolutely. Visit [Create][5] to start.<br><br>\n\n**Don’t see your question here?** [Ask us!][6] \n\n\n  [1]: /dashboard/collect/survey/6136 "Original LAM Diagnosis"\n  [2]: /dashboard/collect/survey/6121 "Existing Medical Information"\n  [3]: /dashboard/collect/survey/5988 "Behavior and Environment"\n  [4]: /dashboard/collect/survey/6072 "Reproductive History"\n  [5]: /dashboard/create/ "Create"\n  [6]: mailto:LAMsightHelp@lamtreatmentalliance.org&subject=FAQ-Collect "Ask us!""
msgstr "如何使用“收集”\n------------------\n\n本网站的“收集”部分用于获取信息。这一功能是 LAMsight 网站的核心任务的关键所在－－以一种全新的途径从全球 LAM 患者族群中收集疾病信息，通过提出研究问题以及使一些因素（例如某些症状）的重要性充分凸显，进而让研究者在更多患者病历数据汇总的基础上形成对疾病本质的新认识和新疗法。本网站提供的信息将供患者和研究者协同使用以了解 LAM 的病因和延缓乃至遏止该病的方法。<br><br>\n\n该部分由几份互动式问卷组成，这些问卷可以在您回答过程中依据您的答案而自动调整问题。因为我们在不断努力改进这些问卷，所以请您在回答时点击每个问题旁边的“评论”图标以对我们的问题做出反馈。请告诉我们您认为这些问题是否清楚、实用、有趣等等。<br><br>\n\n常见问题\n--------------------------\n\n**如何开始？**<br><br>\n\n在您填写完用户首选项之后，请继续向下填写四份优先的问卷：\n\n- [原始 LAM 诊断][1]\n  - [现有医疗信息][2]\n  - [生活习惯与环境因素][3]\n  - [生育史][4]\n\n**完成每份问卷需要多久？**<br><br>\n\n完成问卷的时间长短因回答者和问卷的不同而异。您可以通过屏幕右侧的页面列表查看自己回答问卷的进展（即，您已完成的内容和还有多少问题尚待回答）。我们争取把问卷篇幅控制在一到两个页面之内。我们还会隐藏与您无关的信息。您可以通过点击页面顶端的“下一步”和“上一步”按钮安全地在问卷的各页间进退。您也可以在任意时间离开和回到问卷页面，您填写的内容将被保存。<br><br>\n\n**我可以先保存自己的信息，稍后再完成问卷吗？**<br><br>\n\n可以。在每一个问题结尾，您都有三种选择：\n\n  - “继续回答下一问题，”\n  - “保存，稍后继续，”\n  - “清除答案。”\n\n**我可以在一份已完成的问卷中更改自己的回答吗？**<br><br>\n\n可以，您可以在任何时间返回问卷来更改您的回答。我们确实有一份保密的先前回答历史记录以确保数据的完整性，但在人们使用 LAMsight 网的“探索”部分时，网站提供的数据中只会显示您最近更新的回答。<br><br>\n\n**我必须填完所有问卷吗？**<br><br>\n\n不用。<br><br>\n\n**哪些人有权读取已完成的问卷？**<br><br>\n\n您的个人信息只有您本人和 MIT 网站管理员在出于技术目的时可以读取，绝不会泄露给第三方。您的数据在“探索”部分只会以集合（即集中）型和非身份性（即没有个人详细信息）数据的形式显示给研究者。更多细节请参阅我们的隐私政策。<br><br>\n\n**我对调查问卷已经有所了解。我可以填写一份吗？**<br><br>\n\n当然可以。访问 [创建][5] 以开始。<br><br>\n\n**看不到问题？** [联系我们！][6] \n\n\n  [1]：/dashboard/collect/survey/6136 “原始 LAM 诊断”\n  [2]：/dashboard/collect/survey/6121 “现有医疗信息”\n  [3]：/dashboard/collect/survey/5988 “生活习惯与环境因素”\n  [4]：/dashboard/collect/survey/6072 “生育史”\n  [5]：/dashboard/collect “创建”\n  [6]：将电子邮件发至：LAMsightHelp@lamtreatmentalliance.org&subject=FAQ-Collect “联系我们！”"

# ARTICLE TITLE
#: 25303 TITLE
msgid "Explore: Help and FAQ"
msgstr "探索：帮助和常见问题"

# ARTICLE CONTENT
#: 25303 CONTENT
msgid "How to Use Explore\n------------------\n\nThe “Explore” section of the site is designed to provide researchers and patients with compiled survey data in aggregated (i.e., collective) form. We are currently working on significant feature enhancements. For now, the Explore functionality enables patients and researchers to search for data based on keywords from survey questions. Search results summarize the quantity of responses and content of of responses collected from participants on any given question or topic.<br><br>\n\nFrequently Asked Questions\n--------------------------\n\n**Is Explore a search engine?**<br><br>\n\nAlthough Explore works like a search engine, it does more than point you to pages related to your query. Roll your cursor over an entry, and you will see real-time aggregated results from survey questions. In addition, easy-to-use drag-and-drop filters allow you to compare results of specific sub-populations of patients (e.g, exercisers/nonexercisers).<br><br>\n\n**Don’t see your question here?**\n[Ask us!][1]\n\n\n  [1]: mailto:LAMsightHelp@lamtreatmentalliance.org&subject=FAQ-Collect "Ask us!""
msgstr "如何使用“探索”\n------------------\n\n本网站的“探索”部分用于向研究者和患者提供集合（即集中）型的、整理后的问卷数据。我们目前正努力以优化这一功能。目前，“探索”部分的主要功能是让患者和研究者依据问卷中的关键字搜索数据。搜索的结果总结了从调查参与者处收集的对于任何一个给定问题或话题的回答的数量和内容。<br><br>\n\n常见问题\n--------------------------\n\n**“探索”是搜索引擎吗？**<br><br>\n\n虽然“探索”的工作方式类似搜索引擎，但它能做的不仅是为你指出与您检索内容相关的页面。在某个输入的内容上滚动鼠标指针，您就会看到从问卷问题中实时收集的结果。此外，通过简便易用的拖拽式过滤器，您可以比较不同患者亚群之间的结果（例如坚持锻炼者/不锻炼者）。<br><br>\n\n**此处看不到问题？**\n[联系我们！][1]\n\n\n  [1]：将电子邮件发至：LAMsightHelp@lamtreatmentalliance.org&subject=FAQ-Collect “联系我们！”"

# ARTICLE TITLE
#: 25304 TITLE
msgid "Create: Help and FAQ"
msgstr "创建：帮助和常见问题"

# ARTICLE CONTENT
#: 25304 CONTENT
msgid "How to Use Create\n-----------------\n\nThe “Create” section of the site allows users to create and publish new surveys to LAMsight.<br><br>\n\nThe Survey Editor presents a series of views, each listing a number of possible actions at the right-hand side of the screen. Surveys are made up of Groups, and each Group is made up of individual Questions. The Survey Editor allows you to see, review, and change each of these components of a survey.<br><br>\n\nThe Scratchpad is a space where you can store Groups and Questions that you want to move them from one survey to another.<br><br>\n\nFrequently Asked Questions\n--------------------------\n\n**Why would I create a new survey?**<br><br>\n\nReasons for creating a survey are as varied as the LAMsight community. As you uncover new aspects of issues from your experience with LAM that may be interesting to researchers and, as new questions for patients emerge from researchers, you can use the Survey Editor to build new surveys for the community.<br><br>\n\nAs questions and surveys evolve, previously overlooked aspects of the disease may emerge, giving researchers valuable clues and new insights into the disease and potential treatments.<br><br>\n\n**How do I create a survey?**<br><br>\n\nOn the “Create” page, click “Create New Survey” and, when prompted, enter a name and a brief description for your new survey. You can then choose from several options to build your survey:<br><br>\n\n  - Add New Group (create a new Group\n    for survey elements that have not\n    yet been used)\n  - Add Existing Group (re-use elements\n    from existing surveys to build your\n    survey)\n  - View Diary\n  - Manage Surveys\n\nIt will be helpful to read and complete some existing surveys before creating a new one. By gaining some familiarity with the existing surveys, you will learn much about their basic structure and content, and also will see how others have phrased their Groups and Questions – all of which may be useful as you create your own survey.<br><br>\n\n**What is the Scratchpad?**<br><br>\n\nThe Scratchpad is a place to store Groups and Questions as you build your surveys. To place a Group or Question onto the Scratchpad, simply drag the item from your central panel and drop it onto the Scratchpad.<br><br>\n\n(Note that a Question can only have one parent, so when you drag it back to a different Group, it will disappear from the first.)<br><br>\n\n**Don’t see your question here?**\n[Ask us!][1]\n\n\n  [1]: mailto:LAMsightHelp@lamtreatmentalliance.org&subject=FAQ-Collect "Ask us!""
msgstr "如何使用“创建”\n-----------------\n\n本网站的“创建”部分允许用户自行在 LAMsight 中创建和发布新的调查问卷。<br><br>\n\n用于“创建”的问卷编辑器可显示一系列视图，每一视图在屏幕右侧都列出一组可进行的操作。问卷由若干个群组构成，而每个群组又由若干独立问题构成。通过问卷编辑器，您可以查看、复审和更改问卷中的每一组成部分。<br><br>\n\n您可以用编辑器中的“暂存器”把您想从一份问卷移动到另一份问卷的群组和问题暂时存储起来。<br><br>\n\n常见问题\n--------------------------\n\n**为什么我要创建新问卷呢？**<br><br>\n\n在 LAMsight 社团中，创建新问卷的理由多种多样。当您公开未曾报道过的、且可能是研究者很关注的您的 LAM 病情的新特性时，当关于患者的新问题涌现在研究者面前时，您可以用问卷编辑器为 LAM 社团创建新的调查问卷。<br><br>\n\n随着问题和问卷的不断更新，先前被忽视的一些疾病特性将被暴露出来，这可以给研究者提供有价值的线索和对 LAM 及其可能疗法的深入认识。<br><br>\n\n**我如何创建新问卷？**<br><br>\n\n在“创建”页面上，点击“创建新问卷”并按提示输入新问卷的名称和简介。接下来您可以通过几种不同选项创建您的问卷：<br><br>\n\n  - 添加新群组（为问卷中\n    尚未使用的单元\n    创建新的群组）\n  - 添加已有群组（重复使用\n    已有问卷中的某些单元\n    来创建您的问卷）\n  - 查看日志\n  - 管理调查问卷\n\n通过先行阅读和填写已有问卷来指导自己创建新问卷。通过熟悉已有问卷，您可以更好地了解其基本结构和内容，以及他人如何编排群组和问题--所有这些在您创建自己的问卷时都会有所帮助。<br><br>\n\n**什么是暂存器？**<br><br>\n\n暂存器是在您创建新问卷时用于存储群组和问题的一个区域。要将某个群组或问题存入暂存器，只需用鼠标从您的中央面板将要存储的项目拖放到暂存器图标上即可。<br><br>\n\n（请注意，一个问题只能归属于一个群组，因此当您将其拖动到另一个群组时，它将从前一个群组中消失。）<br><br>\n\n**此处看不到问题？**\n[联系我们！][1]\n\n\n  [1]：将电子邮件发至：LAMsightHelp@lamtreatmentalliance.org&subject=FAQ-Collect “联系我们！”"

# ARTICLE TITLE
#: 25305 TITLE
msgid "Forums: Help and FAQ"
msgstr "论坛：帮助和常见问题"

# ARTICLE CONTENT
#: 25305 CONTENT
msgid "How to Use Discuss\n------------------\n\nThe “Discuss” section of the site allows users to have conversations about surveys, ask questions, share observations, and get help. You can enter posts in each of these respective discussion areas or create a new discussion topic by posting it to the Discussion section of LAMsight. If you have support-related issues, the LAMsight administrative team will aim to reply to your post within 24 hours.<br><br>\n\nFrequently Asked Questions\n--------------------------\n\n**Can I be notified when someone responds to one of my posts?**<br><br>\n\nYes.  In your user preferences there is a “Contact” tab.  The first section of this tab asks if you would like e-mail updates for new forum posts.  If you click “Yes,” then you can choose from daily, weekly, and monthly digests of posts.  You will then receive e-mails from the site with post text and a list of links for forums you have posted in since the last update. (In the future we will allow you more flexibility to filter which forums you get notified about).<br><br>\n\n\n**Don’t see your question here?**\n[Ask us!][1]\n\n\n  [1]: mailto:LAMsightHelp@lamtreatmentalliance.org&subject=FAQ-Collect "Ask us!""
msgstr "如何使用“讨论”\n------------------\n\n本网站的“讨论”部分为用户提供一个谈论问卷、提出问题、分享观点和寻求帮助的平台。您可以在上述各讨论区域中发帖，或在 LAMsight 的“讨论”部分通过发帖创建新的讨论话题。如果您需要支持，LAMsight 管理团队将争取在 24 小时内回复您的帖子。<br><br>\n\n常见问题\n--------------------------\n\n**有人回复我的帖子时能否通知我？**<br><br>\n\n可以。在您的用户首选项中有一个“联系”标签。该标签的第一部分询问您是否希望接受论坛新帖更新提示的电子邮件。如果您点击“是”，则可选择按天、按周和按月查看新帖。此后您就将收到网站的提示邮件，邮件中包含您发帖的论坛最近一次更新后的帖子正文和论坛链接列表。（今后，我们将努力使您能更有针对性地筛选出希望得到提示的论坛）。<br><br>\n\n\n**此处看不到问题？**\n[联系我们！][1]\n\n\n  [1]：将电子邮件发至：LAMsightHelp@lamtreatmentalliance.org&subject=FAQ-Collect “联系我们！”"

# ARTICLE TITLE
#: 25306 TITLE
msgid "Take a short tour of LAMsight"
msgstr "快速浏览 LAMsight"

# ARTICLE CONTENT
#: 25306 CONTENT
msgid "**A new knowledge base created by and for the global LAM community** – LAMsight offers patients and researchers four ways to collaborate.<br><br>\n\n**Take a tour of LAMsight:**<br><br>\n\n**Collect**<br>\n*The heart of LAMsight.* Here you can report the physical and lifestyle issues you experience living with LAM. Easy-to-use interactive surveys cover a wide range of topics, including medicines (including complementary and alternative therapies), diet, exercise and fitness, environment, and other factors.<br><br>\n\n*Your personal information is available only to you and to the MIT site administrators for technical purposes. Your data are visible only in an aggregated form in the Explore interface and in a de-identified form to researchers. See our Privacy Policy for more detail.*<br><br>\n\n**Explore**<br>\n*Ask LAMsight a question.* In the Explore section, you can access aggregate data compiled from questions answered by patients around the globe. Results summarize the content and responses collected from participants on any given question or topic.<br><br>\n\n**Discuss**<br>\n*Connect and share.* Visit this section to discuss surveys, ask questions, and share observations. Discussions are organized around key topics, including “How to Use LAMsight” and “Feature Requests.” Contribute to existing discussions and create new forum topics.<br><br>\n\n**Create**<br>\n*Add to the knowledge base.* As you uncover new aspects of your experience with LAM that may be interesting to researchers, and as new questions for patients emerge for researchers, use the Survey Editor to build new surveys for the community. As questions and surveys evolve, previously overlooked aspects of the disease may emerge, giving researchers valuable clues and insights into LAM and how to slow and stop progression.<br><br>\n"
msgstr "**由全球 LAM 社团创办并为其自身服务的崭新知识库** – LAMsight 为患者和研究者提供四种合作途径。<br><br>\n\n**浏览 LAMsight：**<br><br>\n\n**收集**<br>\n*LAMsight 的核心。* 在该部分您可以报告自己患 LAM 时经历的身体方面和生活方式方面的问题。简便易用的互动式问卷涉及了广泛的话题，包括医药（含补充和替代治疗）、饮食、锻炼和健身、环境以及其它因素。<br><br>\n\n您的个人信息只有您本人和 MIT 网站管理员在出于技术目的时可以读取。您的数据在“探索”部分只会以集合型显示在“探索”界面并以非身份性数据的形式显示给研究者。更多细节请参阅我们的隐私政策*<br><br>\n\n**探索**<br>\n*向 LAMsight 提出问题* 在“探索”部分，您可以获取从全球患者回答的提问中整理出的集中数据。搜索结果总结了从问卷参与者处收集的对于任何一个给定问题或话题的回答的数量和内容。<br><br>\n\n**讨论**<br>\n*联系和共享*访问该部分以讨论问卷、提出问题和分享观点。 讨论是围绕关键话题展开的，包括“如何使用 LAMsight”和“功能申请”。参与现有讨论并创建新的论坛主题。<br><br>\n\n**创建**<br>\n*添加至知识库。*当您公开未曾报道过的、且可能是研究者很关注的您的 LAM 病情的新特性时，当关于患者的新问题涌现在研究者面前时，请用问卷编辑器为 LAM 社团创建新的调查问卷。随着问题和问卷的不断发展更新，先前被忽视的一些疾病特性将被显露出来，这可以给研究者提供关于 LAM 的有价值的线索和深入认识以及延缓乃至遏止该病发展的启示。<br><br>\n"

# ARTICLE TITLE
#: 25431 TITLE
msgid "LAMsight Tour"
msgstr "LAMsight 浏览"

# ARTICLE CONTENT
#: 25431 CONTENT
msgid "This is the public tour"
msgstr "这是公共浏览内容"

# ARTICLE TITLE
#: 27714 TITLE
msgid "LAMsight Development Status"
msgstr "LAMsight 发展状况"

# ARTICLE CONTENT
#: 27714 CONTENT
msgid "A Brief Note from the Site Administrators\n========================================\n\nWe are very excited that you are choosing to register with LAMsight and participate in our community.  LAMsight has been tested over the past two months by a small number of patients and this is the first time that we are opening it up to a large user community.<br><br>\n\nWe anticipate that there will be some bumps growing pains as we dramatically grow our user population and your feedback is crucial to helping us make LAMsight into a resource that serves patients, researchers and clinicians alike.  <br><br>\n\nPlease participate in this process of continuous improvement by posting your feedback and thoughts in the forums, and letting us know of any critical problems immediately by sending e-mail to LAMsightHelp@lamtreatmentalliance.org.  (You can click on the Help link in the upper right-hand corner of the screen to send an email to us too).<br><br>\n\nThank you,<br>\nThe LAMsight Administrators"
msgstr "来自网站管理者的简短提示\n========================================\n\n我们对您能注册 LAMsight 网并加入我们的社团倍感欣喜。在过去的两个月中，LAMsight 接受了少数患者的测试，现在是它首次对大规模用户团体开放。<br><br>\n\n我们已经准备好应对网站用户迅速增长的过程中可能不断出现的困难和挫折，而您的反馈也是我们将 LAMsight 建设成为患者、研究者和医生服务的平台所不可或缺的支持。<br><br>\n\n请参与到这一不断改进的进程中来，在论坛上发布您的反馈意见和想法，并在遇到重大问题时立即发送邮件至 LAMsightHelp@lamtreatmentalliance.org 以及时通知我们。（您也可以点击屏幕右上角的“帮助”链接来向我们发送邮件）。<br><br>\n\n谢谢！<br>\nLAMsight 管理员"

# ARTICLE TITLE
#: 30556 TITLE
msgid "About LAMsight"
msgstr "关于 LAMsight"

# ARTICLE CONTENT
#: 30556 CONTENT
msgid "About LAMsight\n--------------\n\n**LAMsight is…**<br><br>\n\n  - A response to researchers who work\n    on LAM, are interested in getting\n    more involved, but express that they\n    would benefit from more direct\n    access to unidentified data about\n    LAM patients and the disease\n  - A response to more than 26\n    individual patient databases that\n    exist globally but are not\n    harmonized nor or easily accessible\n    to researchers\n  - A response to researchers and\n    clinicians who mourn that there are\n    “too few patients” to learn anything\n    powerful about the disease without\n    investing time and money that\n    neither researchers or patients have\n  - A response to research that says\n    patients oftentimes feel more\n    comfortable sharing accurate health\n    information with computers than with\n    their physicians\n  - A response to patients’\n    extraordinary expertise in their own\n    disease, and to their motivation and\n    commitment to working hard to help\n    research move more quickly\n  - A response to the demand from\n    patients throughout the world to be\n    visible to the research community,\n    if for no other reason they want to\n    be notified and considered early\n    when new clinical trials are being\n    considered or getting underway\n  - A response to patients who want to\n    share and learn from one another in\n    an information-rich, data-based\n    format\n\nLAMsight is a gift to the LAM community, here for the community to make use of new ways that support treatment research!<br><br>\n\nLAMsight is yours…LAMsight is YOU!<br><br>\n\n**Who Helped Create LAMsight?**<br><br>\n\nThe LAMsight Community was conceived collaboratively by the [LAM Treatment Alliance][1] and the Massachusetts Institute of Technology (MIT). It is a purely not-for-profit project intended to foster openness and collaboration among all members of the global LAM community – patients, family-members, researchers, and clinicians.<br><br>\n\n  - Development of LAMsight took place\n    over the course of a year with\n    ongoing feedback from approximately\n    45 members of the global LAM\n    community.\n  - The inspiration for the site, site\n    concept, and demonstrations have\n    been presented at\n    patient/researcher/clinician summits\n    held in five countries. LAMsight\n    will continue to provide webcast\n    opportunities for live feedback from\n    the global patient and researcher\n    community.\n  - LAMsight is a work in progress and\n    your feedback has and will continue\n    to strengthen its impact.\n\nThe LAM Treatment Alliance, founded in 2005, drives an aggressive research agenda solely focused on fast-tracking LAM treatment / cure in time for patients now living with LAM. The LAM Treatment Alliance fosters and funds strategic partnerships with patients, global leaders in LAM research, academic experts in relevant fields, pharma and biotech partners, and other disease-focused foundations in order to have greatest impact on treatment and cure for this fatal disease in the shortest time.<br> <br>\n\nAfter over a year of vetting partners for LAMsight, it was clear that MIT had the ideal mix of brain, brawn, and impact-focused vision to take on this project. The primary developer of the LAMsight web portal is Ian Eslick, a doctoral student in the [New Media Medicine][2] group at the MIT Media Laboratory.<br><br>\n\nIn consultation with the LAM Treatment Alliance, LAM patients, researchers, clinicians, advisors, and MIT’s institutional ethics review board, the New Media Medicine group has undertaken this project as a proof-of-concept study of how to use web technology to advance research in rare diseases.<br><br>\n\n**How Can LAMsight Help Patients?**<br><br>\n\nLAMsight enables patient investigation. Instead of completing repeated forms from patient organizations, LAMsight can be used to store data from the entire global LAM patient population where both patients and researchers can access it with few hurdles in a privacy protected way. Patients can use LAMsight to learn about issues and experiences that interest them and their fellow patients. Patients can ask questions of their peers throughout the world and see various trends in data through pictures, graphs, and charts.<br><br>\n\nLAMsight enables patients to contribute to research happening now and makes it possible for them to be contacted if they qualify for future clinical trials, if they so desire.<br><br>\n\nEven if a patient is unsure about how to get involved, the site is a place where one can explore and determine how LAMsight can best serve her individual interests. Patients can choose and control the amount of information that feels right to disclose, all in a privacy-protected way. Patients will be able to export their data and provide that to patient organizations or to clinicians efficiently, which will help to reduce the burden of repeated requests for data. LAMsight will enable patients to learn and to share important insights and experiences with LAM.<br><br>\n\n**How Can LAMsight Help Researchers?**<br><br>\n\nPatients know their disease best. LAMsight enables patients to teach investigators about what researchers may be interested in and overlooking, thus building a more effective bridge and eliminating misconceptions and gaps in treatment. Through what they learn about us on LAMsight, researchers will be able to ask new questions, learn more about patients, and how patients live with the disease, experience symptoms, and cope.<br><br>\n\nIn turn, the information that researchers can access on LAMsight can motivate important new areas of research. Many researchers, especially those who see a limited number of LAM patients (if any), talk about the difficulty they have finding the most basic information about the global patient population or patients fitting various criteria. Researchers have commented that in many cases they have become discouraged from pursuing work in the field without access to this information. They have stated that they would be interested in self-reported anecdotes from patients around the world to further their knowledge, as a starting point.<br><br>\n\nThere are more than 26 separate LAM patient databases that store patient information in different forms throughout the world. At a minimum, LAMsight will be a central index of all patients anywhere in the world across language barriers, organizational, and national lines.<br><br>\n\nResearchers also are concerned about the high costs of doing patient recruitment for formal clinical trials. LAMsight will help to eliminate the guesswork involved in planning a clinical trial and help researchers to find out if a study is worth doing or if a particular study design will be acceptable to potential patient participants.<br><br>\n\n**What Will LAMsight Do with My Information?**<br><br>\n\nLAMsight holds all personally identifiable information in the strictest confidence and will not release information that will identify a patient to any third parties in any form, without the patient’s prior written authorization. The LAM Treatment Alliance does not have access to patient data or personally identifiable information.<br><br>\n\nThe intention is for the data collected in the patient portal of LAMsight (a clinician data entry portal is also currently in development) to be kept for the benefit of everyone in the LAM community long term – continuity and open access are critical to LAMsight’s core mission of accelerating LAM research.<br><br>\n\nCurrently the site only validates the e-mail of a user, asks people to identify their relationship to the LAM community, and then keeps the email address of the user so that we can contact users according to their account preferences. (People on the site can only be contacted according to their preferences and can always anonymously refuse contact by anyone without disclosing their identity).<br><br>\n\nAgain, the only people with access to any of the identifiers/ identifying information are the direct administrators of the site (MIT and approved developers), for technical administrative uses only. Please see LAMsight’s privacy policy.<br><br>\n\n**How Can I Contact LAMsight?**<br><br>\n\nYour feedback is essential to the success of this site: the ease of your experience and LAMsight’s ability to impact the pace of treatment research. We are grateful and eager to be responsive to your feedback and questions. If you have questions or comments about LAMsight, please contact us at: [LAMsightHelp@lamtreatmentalliance.org][3].<br><br>\n\nLAMsight<br>\nMIT Media Laboratory<br>\n20 Ames Street, E15-401 c/o Frank Moss<br>\nCambridge, MA 02139<br>\n[Back to Home][4]\n\n\n  [1]: http://lamtreatmentalliance.org/ "LAM Treatment Alliance"\n  [2]: http://newmed.lamtreatmentalliance.org/ "New Media Medicine"\n  [3]: mailto:LAMsightHelp@lamtreatmentalliance.org "LAMsightHelp@lamtreatmentalliance.org"\n  [4]: / "Back to Home""
msgstr "关于 LAMsight\n--------------\n\n**LAMsight 是在下列形势下应运而生的…**<br><br>\n\n  - 很多从事\n    LAM 研究且有志于\n    深入探索 LAM 的研究者表示他们需要\n    更直接地获取\n    来自 LAM 患者和疾病本身的\n    未记名数据以协助工作\n  - 超过 26 个 \n    患者数据库\n    分布于世界各地，但是它们\n    既无法协调也\n    不易于研究者访问\n  - 很多研究者\n   和医生慨叹\n    “病人太少”且\n    研究工作的时间和金钱投入\n    令研究者和患者都无法承受\n    因而难以在疾病研究中取得突破\n  - 一些研究显示\n    患者往往更愿意\n    通过电脑来分享\n    确切的健康信息\n   而不是与她们的医生分享。\n  - 一些患者\n    对其自身疾病的了解\n    堪比卓越的专家水准，而且她们非常积极和\n    投入地担负起协助\n    医学研究更快发展的工作。\n  - 世界各地的许多患者\n    都希望自己\n    得到医学研究团体的关注\n    如果没有其它原因，她们希望\n    在临床试验\n    设计与进行的过程中\n    组织者能及早获得通知并将她们纳入试验考虑对象\n  - 一些患者希望\n    通过一种信息丰富、基于专业数据的\n    形式\n    分享知识并互相学习\n\nLAMsight 是馈赠给 LAM 社团的礼物，是支持 LAM 治疗研究的新途径和好帮手！<br><br>\n\nLAMsight 是您的…LAMsight 就是您自己！<br><br>\n\n**LAMsight 由谁帮助创办？**<br><br>\n\nLAMsight 社团及网站由 [LAM 治疗联盟][1] 和麻省理工学院 (MIT) 协同创办。它是纯粹的非营利性网站，旨在促进全球 LAM 社团所有成员--患者、患者家属、研究者和医生之间的公开与协作。<br><br>\n\n  - LAMsight 网站\n    在一年的建设过程中\n    通过不断接收来自\n    全球 LAM 社团中约 45 位会员的\n    反馈信息，得已发展。\n- 本网站的设计灵感、网站\n    理念和效果展示\n    已经于\n    在五个国家的举办的\n    患者/研究者/医生峰会上展示过。LAMsight\n    将坚持通过网络\n    为全球的患者和研究者\n    社团提供实时反馈信息的\n    渠道和机会。\n- LAMsight 是不断发展的事业\n    您的反馈已经并将继续\n    加强它的影响力。\n\n成立于 2005 年的 LAM 治疗联盟，启动了一项积极进取的研究计划，其惟一目标就是为正身患 LAM 的患者及时、快速跟进 LAM 药物/疗法。LAM 治疗联盟鼓励和资助患者、全球 LAM 研究领袖、相关领域学术专家、制药和生物技术行业合作者以及其它疾病组织组成战略合作伙伴关系，以在最短时间内在研究这一致命性疾病的药物和疗法中取得最大进展。<br> <br>\n\n在历经一年 LAMsight 合作伙伴遴选之后，麻省理工学院脱颖而出，从头脑、实力和影响力等各方面综合考虑，它是担当此任的最佳选择。LAMsight 门户网站的首席制作人是 MIT 媒体实验室旗下 [新媒体医疗][2] 组的博士生 Ian Eslick。<br><br>\n\n在咨询了 LAM 治疗联盟、LAM 患者、研究者、医生、顾问和 MIT 学术伦理审查委员会等机构和个人后，新媒体医疗组决定将这个项目作为一项概念验证研究项目来进行，以探索如何通过网络技术深入研究罕见疾病。<br><br>\n\n**LAMsight 如何帮助患者？**<br><br>\n\nLAMsight 可以完成对患者的调查。与以往反复地填写患者组织表格的做法不同，LAMsight 可以用于存储全球 LAM 患者族群数据，并让患者和研究者都能通过一种几乎无障碍且保密的方式来获取这些数据。患者可使用 LAMsight 了解自己和病友感兴趣的病例和经验。患者可在全球范围内向自己的病友提问，还可以通过影片、图片和图表发现各种数据趋势。<br><br>\n\n患者可通过 LAMsight 支持现有的研究，并争取在未来新的临床试验开始时，如果自己符合条件并渴望参与就有可能被尽早纳入试验。<br><br>\n\n即使患者不知如何参与，也可通过 LAMsight 网站探索和决定如何让它最好地为自己的利益服务。患者可自行选择和控制她们认为适合公开到网上的信息量，所有步骤都是以保密方式进行的。患者可以输出她们的数据并将其高效地提供给患者组织或医生，这将大大减轻反复申请数据所造成的负担。通过 LAMsight，患者可以掌握和分享关于 LAM 的重要知识和经验。<br><br>\n\n**LAMsight 如何帮助研究者？**<br><br>\n\n最了解病情的莫过于患者本人。通过 LAMsight，患者可以告诉调查者那些研究者们感兴趣的或忽视的信息，从而在两者间搭建更有效的沟通桥梁并消除治疗中的错误认识和不足。基于在 LAMsight 上的所见所闻，研究者将能够提出新问题，并掌握更多关于患者、患病生活、所经历症状和应对的知识。<br><br>\n\n作为结果，研究者从 LAMsight 上获取的信息将促进相关研究进入新的重要领域。许多研究者，特别是那些只能接触少数 LAM 患者的人（若有的话），都谈到过他们寻找全球患者族群或符合不同标准的患者的最基本信息时经历的重重困难。研究者也承认，很多时候他们对在无法获取这些信息的情况下进行漫无边际的探索感到沮丧。他们表示，非常希望得知来自全球的患者自己报告的患病经历，以丰富他们的知识，并作为他们研究的切入点。<br><br>\n\n目前全世界共有超过 26 个独立的 LAM 患者数据库以不同形式储存着患者的信息。至少，LAMsight 可以作为世界各地患者的跨越语言障碍、组织和国家界线的中心索引工具。<br><br>\n\n研究者在招募患者进行正式临床试验中所投入的巨额成本也是备受关注的问题。LAMsight 将帮助研究者消除设计临床试验中的许多臆测，并考证某项研究是否值得进行或某项特殊研究设计能否为可能参与的患者所接受。<br><br>\n\n**LAMsight 会如何处理我的信息？**<br><br>\n\nLAMsight 将所有个人身份性信息作为最高机密严格保管，在未经患者书面授权之前不会将暴露患者身份的信息以任何形式泄露给第三方。LAM 治疗联盟不能获取患者数据或个人身份性信息<br><br>\n\n此举的目的是为保证从 LAMsight 患者门户（面向医生的数据输入门户目前也在建设中）收集的数据能为长期处在 LAM 社团的每个成员的利益服务－－能持续而开放地读取这些数据对于加快 LAM 研究这一 LAMsight 的核心任务而言至关重要。<br><br>\n\n目前本网站只通过电子邮箱认证用户，要求用户证明其与 LAM 社团之间的关系，然后保存用户邮箱以便我们能根据用户的账户首选项信息与其联系。（本网站成员只能根据其首选项设置来联系，他们也可以随时匿名拒绝与任何人联系而不暴露自己的身份）。<br><br>\n\n我们再次声明，只有本网站的直接管理者（MIT 和经过认证的开发者）仅在出于技术管理目的时，才有权读取任何身份标识/身份性信息。请参阅 LAMsight 的隐私政策。<br><br>\n\n**我如何联系 LAMsight？**<br><br>\n\n您的反馈本网站成功所必不可少的：为您减缓病痛，并赋予 LAMsight 足够的能力来推进疾病治疗研究的进程。我们衷心感谢您的反馈，并非常期待能积极响应您的反馈和提问。如果您对 LAMsight 有疑问或意见，请发送电子邮件至：[LAMsightHelp@lamtreatmentalliance.org][3].<br><br>\n\nLAMsight<br>\nMIT Media Laboratory<br>\n20 Ames Street, E15-401 c/o Frank Moss<br>\nCambridge, MA 02139<br>\n[返回主页][4]\n\n\n  [1]：http://lamtreatmentalliance.org/ “LAM 治疗联盟”\n  [2]：http://newmed.lamtreatmentalliance.org/ “新媒体医疗”\n  [3]：将电子邮件发至：LAMsightHelp@lamtreatmentalliance.org “LAMsightHelp@lamtreatmentalliance.org”\n  [4]：/ “返回主页”"

# ARTICLE TITLE
#: 30804 TITLE
msgid "Estrogen Study Introduction (Public)"
msgstr "雌激素研究简介（面向公众）"

# ARTICLE CONTENT
#: 30804 CONTENT
msgid "<h2> The Impact of Estrogen on LAM </h2>\n\n<p>LAM almost exclusively effects women, yet little is known about the role of the female estrogen and progesterone in the progression of LAM.  A number of LAM patients have anecdotally reported a regular variation in breathing difficulty that they feel is associated with their menstrual cycle.  A question was raised at a recent conference as to whether this is true for more women.  If true, it will provide insights to researchers about the role estrogen and/or progesterone in LAM and may effect the course of future research into potential treatments or cures </p><br>\n\n<p>However, existing data from LAM patients does not provide any insight into short-term changes in breathing difficulty making it difficult for researchers to use these anecdotes to inform their research.</p><br>\n\n<p>Therefore, we hope to conduct a study explore the relationship between breathing difficulty and the hormonal changes associated with the menstrual cycle.  We hope you will be able to assist with our study to further discover information on LAM in hopes of eventually finding a cure for the disease. Below is a short description of what we plan to do with the study and how we will gather data. </p><br>\n\n<p>We will gather information using a background survey and regular reports and measurements, performed by you and entered online.  We ask for a minimum of two measurements: a home spirometer reading, a device familiar to many LAM patients, that provides a numeric measure of lung function (FEV1/FEC), and a thermometer which helps to objectively establish the menstrual rhythm.  Regular recording of this data is necessary to understand the potential short-term impact of hormones on LAM.  We also ask for your thoughts and impressions as the study progresses; these observations can be critical in helping us formulate new and better questions as the study progresses.</p><br>\n\n<p>If you are interested, please visit the <a href= “”>study sign up page </a> to find out more information about our study, including our protocol, as well as to sign up. Anything not covered on this page is addressed by the LAMsight <a href="">privacy policy</a> and <a href="">Terms of Use</a>.</p><br>\n\n<p>Questions about this study can be addressed to: <a href="mailto:LAMsightHelp@lamtreatmentalliance.org">LAMsightHelp@lamtreatmentalliance.org</a> .</p>\n\n\n\n\n\n"
msgstr "<h2> 雌激素对 LAM 的影响 </h2>\n\n<p>尽管 LAM 患者几乎均为女性，但目前人们对女性雌激素和黄体酮在 LAM 病情发展中起到何种作用仍知之甚少。一些 LAM 患者在非正式的报告中指出她们感觉自己的呼吸困难程度随着自己的月经周期呈现有规律的变化。在最近一次会议中，有人提出一个问题：这种现象是否在其他女性患者身上普遍存在？如果事实确实如此，这将对研究者探索雌激素和/或黄体酮在 LAM 中所起的作用产生很大启发，并对未来围绕该病潜在治疗药物和疗法的研究进程产生深远影响。</p><br>\n\n<p>但是，现有的 LAM 患者的数据中没有任何关于呼吸困难状况短期变化的线索，这使得研究者难以使用上述非正式报告来指导研究。</p><br>\n\n<p>因此，我们希望开展一项研究，探索呼吸困难与伴随月经周期的激素变化之间可能存在的关系。我们希望您能支持该项研究，以进一步揭示 LAM 本质，并最终找到治愈该病的方法。以下是一份关于我们如何设计该项研究并收集数据的简介。</p><br>\n\n<p>我们将通过一份背景调查问卷，以及由您操作并在线输入的定期报告和测量结果来收集数据。我们至少需要两项测量数据：一项是家用肺活量计的读数，它是很多 LAM 患者熟知的测量设备，用于将肺功能以数字形式 (FEV1/FEC) 显示出来；另一项是体温计读数，它有助于客观地确定月经周期。定期记录这些数据对探究激素对 LAM 潜在的短期性影响十分必要。在研究进行中我们也会询问您的看法和印象；这些观点非常有助于我们编写更新更好的问卷。</p><br>\n\n<p>如果您感兴趣，请访问<a href= “”>研究签约页面 </a> 以获得关于我们研究项目的更多信息，包括我们的协议，并签署该协议。该页面未能涵盖的任何内容都在 LAMsight 的 <a href="">隐私政策</a> 和 <a href="">使用条款</a> 中作出了相应规定。</p><br>\n\n<p>关于该研究的提问可发送邮件至：<a href="将电子邮件发至：LAMsightHelp@lamtreatmentalliance.org">LAMsightHelp@lamtreatmentalliance.org</a> 。</p>\n\n\n\n\n\n"

# ARTICLE TITLE
#: 30805 TITLE
msgid "Estrogen Study Protocol"
msgstr "雌激素研究协议"

# ARTICLE CONTENT
#: 30805 CONTENT
msgid "<h2>Experimental Protocol:Study: The Impact of Estrogen/Progesterone levels on Pulmonary Function in LAM </h2><br>\n\nPlease read over this protocol carefully to gain a better understanding of the procedures and steps we will use in the estrogen study. We are providing you with a complete protocol so it will answer any questions that may arise while participating in this research study. It includes information regarding our experimental goals, the equipment that will be used, what needs to be accomplished daisy, as well as what will happen at the conclusion of the study. Once you feel that you are comfortable with the information on this protocol, please click the continue button to move onto our consent form. As always, feel free to contact us at <a href="mailto:LAMsightHelp@lamtreatmentalliance.org">LAMsightHelp@lamtreatmentalliance.org</a> if you have any questions regarding the study.\n\n<h4>1. Experimental Goals and Outline</h4>\n<p>The LAM Hormone Study is an exploratory study of the correlation between estrogen/progesterone levels and objective/subjective pulmonary function.  A number of patients have reported a \n\nsubjective variation in breathing difficulty that appears to be correlated to their menstrual cycle.  The goal of the study is to back up this observation with objective data that can be used to assess \n\nthe likelihood of a causal relationship that would motivate further studies as well as focus biological research into the interaction of these hormones in the signaling pathways indicated in \n\nLAM.</p>\n<p><ul>\n<li>We intend to recruit 20-40 patients through advocacy groups and advertisements on LAMsight, a web platform for the LAM community.\n<li>The study will run for 3 to 5 months, the time period based on an assessment of the degree of compliance of the participants and the observed noise in the data set.\n<li>Subjects will sign up for an account on LAMsight, accept an online consent that outlines the goals and procedures of the study as well as the intended use of data and the potential risks of \n\nparticipation vis-a-vis privacy.\n<li>Subjects will request a spirometer and thermometer to be sent to them at their international address. The equipment has been volunteered by an advocacy organization, but will be sent by the \n\nmedia lab to restrict access to private information to Media Lab personnel.\n<li>Subjects will fill out a background questionnaire (attached) which establishes their suitability for the study.  (Selection criterion below)\n<li>Each patient will fill out a daily report on their subject experiences of the prior day and take readings of temperature and lung function each morning, entering these into a form on the LAMsight \n\nplatform.\n<li>At the conclusion of the study, users will receive a final notice with any results from the study to date and the option of separating their submitted data from their account so there is no \n\nidentifiable information left in LAMsight that would allow their identity to be released.  \n<li>A fully de-identified form of the dataset will be made available via a query interface that limits query results to populations greater than 5 people.  The data will be searchable on site, but \n\naggregate reports of these datasets are not identifiable as all identifiers are sequestered from the search and visualization engine.  This interface is available to all users of the site and interested \n\nresearchers.  The privacy policy on the site clearly indicates that any data entered on the site will be so-available and all users will have consented to this policy as part of the registration process.\n</ul></p>\n\n<h4>2. Equipment</h4>\n<p>The equipment used for this study consists of a simple home thermometer and a spirometer.</p>\n<p><ul>\n<li>The spirometer used is the Piko-6, a simple low-cost device that measures 1-second Forced Expiratory Volume (FEV1) and the six second equivalent (FEV6).  This device is typically used for \n\nhome monitoring of asthma patients.  The device is roughly 1”x2”x3”.\n<li> The thermometer used is.......\n</ul></p>\n\n<h4>3.Daily Protocol</h4>\n\n<p>Subjects will fill out the daily survey form (attached) each morning preferably after they wake.  The questionnaire includes the time they woke up and the time of test.  They will measure their \n\nbody temperature using thermometer under the tongue for N seconds.  The subject will then perform a test with the spirometer three times, entering the FEV1 and FEV6 results into the questionnaire \n\nform for each result.</p>\n\n<h4>4. Completion of the Study</h4>\n\n<p>At the completion of the study users will be sent a summary of the study results along with an indication that they can request removal of all identifiable data or all submitted data.  They can \n\nalso request an electronic version of their entries over the study period.</p>\n\n<h4>5. Modifications to the Study Protocol</h4>\n\n<p>We do not anticipate material changes to the study protocol after this application is submitted.  Given the nature of the online site, we may be able to draw on additional background information \n\nvoluntarily entered by users.  We will submit a request for an expedited review in the event we choose to utilize such information, or to add any additional data requests to the reviews attached to \n\nthis application.  We will submit a request for a full review if any changes may effect the privacy considerations already addressed by this protocol.</p>\n\n\n\n"
msgstr "<h2>试验性协议：研究：雌激素/黄体酮水平对 LAM 患者肺功能的影响 </h2><br>\n\n请仔细阅读本协议，以更好地了解我们在雌激素研究中采用的程序和步骤。我们在此提供的是完整协议，它能回答参与该研究时可能出现的所有问题。它的信息涵盖了我们的实验目的、所使用仪器、需要首先完成的工作以及研究结束时可能发生的事情。如果您对该协议的条款满意，请点击“继续”按钮进入同意书表格页面。同样地，如果您对该研究有任何疑问，请随时致信 <a href="将电子邮件发至：LAMsightHelp@lamtreatmentalliance.org">LAMsightHelp@lamtreatmentalliance.org</a> 联系我们。\n\n<h4>1. 试验目的和纲要</h4>\n<p>“LAM 激素研究”是针对雌激素/黄体酮水平与客观/主观肺功能之间的联系进行的探索性研究。据一些 LAM 患者报告 \n\n其呼吸困难程度的主观感受会与月经周期协同变化。该项研究的目的就是为这一主观感受提供客观数据的支持，从而 \n\n考证二者间存在因果关系的可能性，这将推动研究进一步深入，并使生物学研究集中于 LAM 所表明的 信号转导通路中的激素的 \n\n交互作用。</p>\n<p><ul>\n<li>我们准备通过医疗倡导团体和在 LAM 社团的网络平台－－LAMsight 上发布广告来招募 20-40 名患者。\n<li>该研究将持续 3 至 5 个月，具体时间长短依据对参与者合作程度和对数据集里观测噪音的评估而定。\n<li>研究参与者需要在 LAMsight 上注册一个账户，并在线签署一份列出研究目的和程序、数据预期用途以及 \n\n参与研究与隐私权相对比的潜在风险\n 的同意书。<li>参与者需申请将一个肺活量计和一个体温计邮寄至她们的国际地址。这些设备是由一个倡导组织无偿赞助的，但它们须由 \n\n媒体实验室邮寄以确保参与者的私人信息仅限媒体实验室内部人员知晓。\n<li>受试者将填写一份背景问卷（附后）以确认其适合参加该研究。（选择标准见下）\n<li>每位患者每天都要填写报表，报告前一天的主观感受，并在每天早上记录自己的体温和肺功能读数，将其输入 LAMsight \n\n网络平台的相应表格中。\n<li>在研究结束时，参与者将收到一份最终通知，上面写有截至结束日的所有研究结果以及询问她们是否将自己提交的数据从其账户中分离以 \n\n消除 LAMsight 网站上可能暴露其身份的信息。\n<li>一份绝对去识别化的数据集表格可以通过一个询问界面获取，该界面只能显示 5 人以上的多人询问结果。这些数据可以从本网站内搜索到，但 \n\n数据集的集中报告都是去识别化的，因为所有身份标识都已从搜索和显示引擎中屏蔽掉。该界面对所有网站用户和感兴趣的 \n\n研究者开放。本网站隐私政策明确指出，所有输入到本网站上的数据都是可获取的，所有用户在注册过程中都要同意该政策。\n</ul></p>\n\n<h4>2. 设备</h4>\n<p>本研究中需要使用的设备包括一支简易家用体温计和一个肺活量计。</p>\n<p><ul>\n<li>其中肺活量计是简易廉价的 Piko-6 型设备，用于测量 1 秒钟用力呼气量 (FEV1) 和 6 秒等效呼气量 (FEV6)。该设备常用于 \n\n哮喘患者的家庭监控。该设备的尺寸约为 1”x2”x3”。\n<li> 研究使用的体温计是.......\n</ul></p>\n\n<h4>3.每日协议</h4>\n\n<p>参与者需填写每日问卷表格（附后），填写的最佳时间是每天早晨起床之后。该问卷表包含受试者起床的时间和进行测量的时间。受试者需将体温计放在自己的 \n\n舌下，保持 N 秒后记录体温。接下来，受试者要用肺活量计进行三次测量，并将测得的 FEV1 和 FEV6 结果输入 \n\n相应问卷表格。</p>\n\n<h4>4. 研究结束</h4>\n\n<p>在研究结束时，每位受试者将收到一份研究结果总结以及告知她们可以申请删除所有自己的身份性数据或已提交数据的提示。她们也可以 \n\n申请得到自己在研究过程中录入数据的电子版。</p>\n\n<h4>5. 研究协议的修正</h4>\n\n<p>我们预期在该申请提交之后研究协议的实质性内容不会做出更改。基于在线网站的性质，我们可能会提取到用户自愿输入的 \n\n额外背景信息。我们会在需要使用这些信息时，或需要对该申请之后附加的评论添加额外的数据要求时 \n\n提交一份申请以快速征求用户意见。如果有任何更改可能影响该协议已经明确的隐私权规定，我们都会向用户提交一份申请以征求全体意见。</p>\n\n\n\n"

# ARTICLE TITLE
#: 30806 TITLE
msgid "Estrogen Study Consent Form"
msgstr "雌激素研究同意书表格"

# ARTICLE CONTENT
#: 30806 CONTENT
msgid "<h2 align="center"> CONSENT TO PARTICIPATE IN NON-BIOMEDICAL RESEARCH</h2>\n\n<h3 align="center">The impact of Estrogen/Progesterone levels on pulmonary function in LAM</h3></align>\n\n<p>You are asked to participate in a research study conducted by Frank Moss and Ian Eslick, from the MIT Media Laboratory at the Massachusetts Institute of Technology (M.I.T.).  The results of this \n\nstudy may be used as a part of Eslick's PhD thesis.  You were selected as a possible participant in this study because you have been diagnosed with LAM. You should read the information below, and \n\nask questions about anything you do not understand, before deciding whether or not to participate.</p>\n\n<h4>PARTICIPATION AND WITHDRAWAL</h4>\n<p>Your participation in this study is completely voluntary and you are free to choose whether to be in it or not. If you choose to be in this study, you may subsequently withdraw from it at any \n\ntime without penalty or consequences of any kind.  The investigator may withdraw you from this research if circumstances arise which warrant doing so.  </p>\n<h4>PURPOSE OF THE STUDY</h4>\n<p>LAM is a women only disease, yet little is known about the role of estrogen and progesterone.  LAM patients have self-reported variation in breathing difficulty that they feel is associated with \n\ntheir menstrual cycle.  A question was raised at a recent conference as to whether this is true for many women.  If true, it will provide insights to researchers about the role estrogen and/or \n\nprogesterone in LAM and may effect the course of future research into potential treatments or cures </p>\n<p>Existing data from LAM patients does not provide any any insight into short-term changes in breathing difficulty.  This study is exploring whether a relationship exists between breathing \n\ndifficulty and the hormonal changes associated with the menstrual cycle.  We will gather this data using both patient reports; both a background survey as well as daily logs.  We ask for a minimum \n\nof two measurements: a home spirometer, a device familiar to many LAM patients that provides a numeric measure of lung function, and a thermometer which helps establish the menstrual rhythm.  \n\nRegular recording of this data is necessary to understand the potential short-term impact of hormones on LAM.</p>\n\n<h4>PROCEDURES</h4>\n<p>If you volunteer to participate in this study, we would ask you to do the following things:</p>\n<ul>\n<li>Register for an account on LAMsight; review and accept the terms of use and privacy policy.  Please address any concerns to us at <a href="mailto: LAMsightHelp@lamtreatmentalliance.org">lamsight-\n\nadmin.lamtreatmentalliance.org</a>.\n<li>Fill out the background questionnaire.  This online questionnaire is on LAMsight and can filled in a little at a time as the study progresses.\n<li>Provide a mailing address so that we may send you a spirometer and thermometer to use in the study.\n<li>Select a regular schedule for taking spirometer and temperature readings and filling out a daily questionnaire.  We ask that you commit to at least 4 readings a week and we encourage you to \n\nmake this a daily habit.\n<li>Optionally sign up for e-mail reminders on your chosen days.\n<li>On each morning of your scheduled day, take the spirometer readings and fill out the daily questionnaire.\n<li>We ask you to take 3 readings for each questionnaire.  The system will take an average of the three readings to help reduce errors in the readings.\n<li>The temperature reading will be taken under the tongue.\n<li>The daily questionnaire will ask you for a report of your subject experiences of the prior day and any variations in your daily routine, such as travel, being sick, exercise, etc.\n<li>We will also ask for additional signifcant personal data such as weight which need not be submitted each day.\n</ul>\n\n<p>This study will last for 3 months from its start date. We ask that you commit to 3 months with an optional extension of 2 monthsdepending on a review of the data collected at 3 months. </p>\n\n<h4>POTENTIAL RISKS AND DISCOMFORTS</h4>\n<p>We see little significant risks in this study beyond the following potential discomforts.  You should ensure that you are willing to see the results of daily spirometer readings and accept any \n\npersonal discomfort that may result from this.  Taking daily spirometer readings if you have an advanced case of LAM may be physically tiring.  </p>\n<p>You may withdraw from the study at any time because of these potential discomforts, or for any other reason.  You will have the option of leaving your data in the system or having it \n\nremoved.</p>\n\n<h4>POTENTIAL BENEFITS</h4>\n<p>This study provides you, the patient, with an opportunity to advocate to the research community with data that helps concretize self report.  If this study is successful, it may pave the ways for \n\nother patient driven studies that can change the way patients self-advocate to the research community.</p>\n<p>Moreover, the result of this study could accelerate an avenue of research in LAM by clarifying out a possible link between hormones and the expression of LAM.</p>\n\n<h4>PAYMENT FOR PARTICIPATION</h4>\nThere is no payment or other compensation for participating >in this study.\n\n<h4>CONFIDENTIALITY</h4>\n<p>Any information that is obtained in connection with this study and that can be identified with you will remain confidential and will be disclosed only with your permission or as required by law. \n\n</p>\n<p>A limited amount of personal information such as your e-mail address and physical mailing address are stored in a protected region on the server, unavailable to anyone other than the \n\nadministrators of LAMsight who have all undergone training for interacting with personal information.  By default the information captured in this study will remain associated with your LAMsight \n\naccount but you may choose to have the account anonymized (the information is retained, but all your personal information is removed from the system), or you may choose to have the account \n\ndeleted.  Please see the LAMsight privacy policy for more information about how your information is maintained  by the system's backup system for a period of time.</p>\n<p>By default, data is available to other users on LAMsight in an aggregated form through a search interface.  In no case will your clearly identified private data be available through this interface.  \n\nAs a participant in this study you can choose to have your account hidden from this query and visualiztino system, yet continue to participate in the study.</p>\n<p>The data from this study may be released to other researchers in de-identified form, meaning the data will be disconnected from any personal identifiers using a random numeric code that only \n\nthe site administrators can link back to your account.</p>\n<p>If any additional uses are contemplated that may result in the disclosure of your data to other researchers, we will contact you by e-mail or physical mail to obtain your consent.  No other uses \n\nof the data will be authorized by us without your explicit consent.</p>\n\n<h4>IDENTIFICATION OF INVESTIGATORS</h4>\n<p>If you have any questions or concerns about the research, please feel free to contact:</p>\n<p>Ian Eslick, Research Assistant\n<br>MIT Media Laboratory\n<br>20 Ames Street, E15-320R\n<br>Cambridge, MA 02139\n<br>617-452-5634\n<br><a href="mailto: eslick@lamtreatmentalliance.org">eslick@lamtreatmentalliance.org</a></p>\n\n<p>Frank Moss, Professor of the Practice\n<br>MIT Media Laboratory\n<br>20 Ames Street, E15-401\n<br>Cambridge, MA 02139\n<br><a href="mailto: fmoss@lamtreatmentalliance.org">fmoss@lamtreatmentalliance.org</a></p>\n\n<h4>EMERGENCY CARE AND COMPENSATION FOR INJURY</h4>\n<p>If you feel you have suffered an injury, which may include emotional trauma, as a result of participating in this study, please contact the person in charge of the study as soon as possible.</p>\n<p>In the event you suffer such an injury, M.I.T. may provide itself, or arrange for the provision of, emergency transport or medical treatment, including emergency treatment and follow-up care, as \n\nneeded, or reimbursement for such medical services.  M.I.T. does not provide any other form of compensation for injury. In any case, neither the offer to provide medical assistance, nor the actual \n\nprovision of medical services shall be considered an admission of fault or acceptance of liability. Questions regarding this policy may be directed to MIT’s Insurance Office, (617) 253-2823. Your \n\ninsurance carrier may be billed for the cost of emergency transport or medical treatment, if such services are determined not to be directly related to your participation in this study.</p>\n\n<h4>RIGHTS OF RESEARCH SUBJECTS</h4>\n<p>You are not waiving any legal claims, rights or remedies because of your participation in this research study.  If you feel you have been treated unfairly, or you have questions regarding your \n\nrights as a research subject, you may contact the Chairman of the Committee on the Use of Humans as Experimental Subjects, M.I.T., Room E25-143B, 77 Massachusetts Ave, Cambridge, MA 02139, \n\nphone 1-617-253-6787.</p>\n\n<h4 align="center">SIGNATURE OF RESEARCH SUBJECT OR LEGAL REPRESENTATIVE</h4>\n<p>I understand the procedures described above.  My questions have been answered to my satisfaction, and I agree to participate in this study.  I have been given a copy of this form.</p>\n<br> <br> \n<hr width=400 align=left>\n<p>Name of Subject</p>\n<br> <br> \n<hr width=400 align=left>\n<p>Name of Legal Representative (if applicable)</p>\n<br> <br> \n<hr width=400 align=left><hr width=400 align=right>\n<p>Signature of Subject or Legal Representative</p>\n<br> <br> \n<hr width=400 align=left><hr width=400 align=right>\n<p>Date</p>"
msgstr "<h2 align="center"> 参加非生物医学研究同意书</h2>\n\n<h3 align="center">LAM 中雌激素/黄体酮水平对肺功能的影响</h3></align>\n\n<p>我们邀请您参加由来自麻省理工学院 (M.I.T.) MIT 媒体实验室的 Frank Moss 和 Ian Eslick 主持的研究项目。该研究的 \n\n结果可能在 Eslick 的博士学位论文中被引用。您是该研究项目可能的参与者，因为您被确诊患有 LAM。请您阅读以下信息，并 \n\n在您决定是否参加研究之前，就所有您不理解的问题进行提问。</p>\n\n<h4>参加和退出</h4>\n<p>您参加该研究项目完全是自愿的，并且您可以自由决定是否参加。如果您决定参加该研究，您仍然可以在随后的任意时间 \n\n退出而不会遭受任何处罚或类似后果。研究者也可能出于某些需要而让您退出该研究。</p>\n<h4>研究目的</h4>\n<p>LAM 是一种只局限于女性的疾病，但人们对女性雌激素和黄体酮在该病中所起的作用还知之甚少。一些 LAM 患者主动报告说其感受到的呼吸困难程度变化与 \n\n其月经周期相协同。在最近一次会议中，有人提出一个问题：这种现象是否在其他女性患者身上普遍存在？如果事实确实如此，这将对研究者探索雌激素和/或 \n\n黄体酮在 LAM 中所起的作用产生很大启发，并对未来围绕该病潜在治疗药物和疗法的研究进程产生深远影响。 </p>\n<p>现有的 LAM 患者的数据中没有任何关于呼吸困难状况短期变化的线索。本项研究正是为了探索呼吸 \n\n困难与伴随月经周期的激素变化之间是否存在某种关系。我们将同时使用患者报告、背景问卷和日志来收集此类数据。我们至少需要 \n\n两项测量数据：一项是家用肺活量计的读数，它是很多 LAM 患者熟知的测量设备，用于将肺功能以数字形式 (FEV1/FEC) 显示出来；另一项是体温计读数，它有助于客观地确定月经周期。\n\n定期记录这些数据非常对于探究激素对 LAM 潜在的短期性影响十分必要。</p>\n\n<h4>研究程序</h4>\n<p>如果您自愿参加该研究，请完成以下工作：</p>\n<ul>\n<li>在 LAMsight 网站注册账户；阅读和接受使用条款和隐私政策。如有任何疑问请致信 <a href="将电子邮件发至：LAMsightHelp@lamtreatmentalliance.org">lamsight-\n\nadmin.lamtreatmentalliance.org</a>.\n<li>填写背景问卷。这份在线问卷显示在 LAMsight 网站上，可以随着研究的进展而每次填写一点，分多次填写。\n<li>提供您的邮寄地址以便我们将研究中使用的肺活量计和体温计寄给您。\n<li>遵守每日定时记录肺活量计和体温计读数的时间表，并填写每日问卷。您每周需要记录至少 4 天的读数，最好能养成 \n\n每天记录的习惯。\n<li>选择电子邮件提示频率并接收提示邮件。\n<li>在您参与实验日程的每个早晨，测量自己的肺活量读数并填写每日问卷。\n<li>在每份问卷中记录 3 个读数。数据处理系统将自动取三个读数的平均值已减小读数误差。\n<li>测量体温要取舌下温度。\n<li>在每日问卷中，您要报告自己在前一天的主观感受，以及每天作息常规的变化，例如旅行、生病、锻炼等等。\n<li>我们还会需要某些额外的重要个人数据，例如体重，这些数据无需每日提交。\n</ul>\n\n<p>该研究将持续 3 个月。用户参与该研究 3 个月期满时，将依据对前 3 个月收集数据的评估决定是否再延长 2 个月的研究时间。</p>\n\n<h4>潜在的风险和不适</h4>\n<p>除了下列可能出现的不适之外，本研究几乎没有任何重大风险。请确保您愿意看到每日的肺活量计读数，并能接受任何 \n\n由此给自己带来的不适。如果您患有晚期 LAM，则每天记录肺活量计读数可能令您身体感到疲劳。</p>\n<p>由于这些可能出现的不适或其它任何原因，您都可以在任意时间退出该研究。您可以选择在该系统中保存自己的数据或将其 \n\n删除。</p>\n\n<h4>潜在利益</h4>\n<p>该研究将为身为患者的您提供一次机会，以通过规范自我报告的数据来推动疾病研究进展。如果该研究成功了，它将为 \n\n其他患者启动的研究开辟道路，从而改变患者主动推进疾病研究的方式。</p>\n<p>而且，该研究的结果将揭示激素与 LAM 症状之间可能存在的联系，从而加快 LAM 研究的进程。</p>\n\n<h4>参加报酬</h4>\n参加本项研究不能获得任何报酬或补助金。\n\n<h4>保密性</h4>\n<p>所有从本研究中获得的、可能透露您身份的信息都是严格保密的，只在您授权许可或法律要求时才会公开。\n\n</p>\n<p>某些有限的个人信息，例如您的电子邮箱和邮寄地址等都保存在服务器的一个保护区内，除了 \n\n 接受过处理个人信息的全套培训的 LAMsight 管理员之外，其他任何人都无法获取这些信息。在默认情况下，本研究中收集的信息将继续与您 LAMsight \n\n账户保持关联性，但您可以选择让账户匿名化（仍保留研究信息，但将您的一切个人信息从系统中删除），或者直接将账户 \n\n删除。关于您的信息如何在网站系统的备份区保存一段时间，请参阅 LAMsight 隐私政策以获得更多信息。</p>\n<p>在默认值情况下，LAMsight 其他用户可通过搜索界面获取集合型数据。您的确切个人身份性信息绝不会在该界面中泄露。\n\n作为研究受试者，您可以选择在本网站的查询和可视化系统中隐藏自己的账户，但仍可参与研究。</p>\n<p>该研究的数据可能以去识别化的形式公布给其他研究者，也就是说，这些数据将使用随机数字代码编号，从而与个人身份标识分离，只有 \n\n网站管理员可以通过这组数字代码找到您的账户。</p>\n<p>如有任何附加的用途可能导致您的数据被泄露给其他研究者，我们都会通过电子邮件或实物信件联系您以征求您的同意。未经您的专门许可，我们不会授权任何人 \n\n使用您的数据。</p>\n\n<h4>调查者身份</h4>\n<p>如果您对本研究有任何疑问或担心，请随时联系：</p>\n<p>Ian Eslick，Research Assistant\n<br>MIT Media Laboratory\n<br>20 Ames Street, E15-320R\n<br>Cambridge, MA 02139\n<br>617-452-5634\n<br><a href="将电子邮件发至：eslick@lamtreatmentalliance.org">eslick@lamtreatmentalliance.org</a></p>\n\n<p>Frank Moss, Professor of the Practice\n<br>MIT Media Laboratory\n<br>20 Ames Street, E15-401\n<br>Cambridge, MA 02139\n<br><a href="将电子邮件发至：fmoss@lamtreatmentalliance.org">fmoss@lamtreatmentalliance.org</a></p>\n\n<h4>急救护理和伤害赔偿</h4>\n<p>如果您感到自己在参加研究过程中受到伤害，其中包括感情创伤，请尽快联系研究负责人。</p>\n<p>如果您受到此类伤害，M.I.T. 将应您的需求亲自或安排他人提供急救转运或治疗，包括急救治疗和后续护理，\n\n或为您报销这些医疗服务的费用。M.I.T. 不会支付任何其它形式的伤害赔偿。任何情况下，主动提供医疗援助或实质性提供 \n\n医疗服务都不能视为承认错误或承担责任。关于这项政策的问题可以咨询 MIT 保险办公室：(617) 253-2823。 \n\n如果这些服务被认定为不与参加本项研究直接相关，那么您的保险公司可能支付急救转运或治疗费用。</p>\n\n<h4>研究受试者权利</h4>\n<p>您不会因为参与本项研究而放弃任何合法要求、权利或补偿。如果您感觉自己受到不公正待遇，或者您对自己作为研究受试者的权利 \n\n存在疑问，请联系“以人为试验对象”委员会的主席，联系方式：M.I.T., Room E25-143B, 77 Massachusetts Ave, Cambridge, MA 02139, \n\n电话：1-617-253-6787。</p>\n\n<h4 align="center">研究受试者或法定代表签字</h4>\n<p>我已理解上述程序。我的问题已得到满意答复，我同意参加此项研究。我已得到该表格的复印件。</p>\n<br> <br> \n<hr width=400 align=left>\n<p>受试者姓名</p>\n<br> <br> \n<hr width=400 align=left>\n<p>法定代表人姓名（如果有）</p>\n<br> <br> \n<hr width=400 align=left><hr width=400 align=right>\n<p>受试者或法定代表签字</p>\n<br> <br> \n<hr width=400 align=left><hr width=400 align=right>\n<p>日期</p>"

# ARTICLE TITLE
#: 31372 TITLE
msgid "Estrogen Study Introduction (Private)"
msgstr "雌激素研究简介（私密）"

# ARTICLE CONTENT
#: 31372 CONTENT
msgid "<h2> The Impact of Estrogen on LAM </h2>\n\n<p>Thank you so much for expressing interest in our study to determine the relationship between estrogen hormone levels and the symptoms of LAM. As you know, a number of LAM patients have anecdotally reported a regular variation in breathing difficulty that they feel is associated with their menstrual cycle. However, existing data from LAM patients does not provide any insight into short-term changes in breathing difficulty making it difficult for researchers to use these anecdotes to inform their research.</p><br>\n\n<p>For this study, we will gather information using a background survey and regular reports and measurements, performed by you and entered on this website. We will create an estrogen study home page specifically made for this research study. We ask for a minimum of two measurements: a home spirometer reading, that provides a numeric measure of lung function (FEV1/FEC), and a thermometer which helps to objectively establish the menstrual rhythm. Because it is imperative that we receive regular consistent readings, we would like to give you the option of receiving reminder emails each day to conduct the measurements. These reminder emails are completely optional but will allow us to gather data on a more consistent basis. <p><br>\n\n<p>Currently, we are in the recruitment phase of this study to gather a sample patient population. We will continue to recruit until the end of May, when we will assemble the testing kits to be delivered to each volunteer. The kit will contain a spirometer to measure lung function, a thermometer to measure basal body temperature to keep track of estrogen levels, as well as a more extensive information packet regarding LAM and this study.</p><br>\n\n<p>A full description of the study can be found <a href="">here</a>.  If you wish to participate, please click [here] to continue on to read the protocol and consent form and  to sign up for the study.  The consent form outlines your rights as a contributor to this study, how to receive your spirometer and thermometer, and how we will safeguard your personal information.  Anything not covered by the consent form is addressed by the LAMsight <a href="">privacy policy</a> and <a href="">Terms of Use</a>.</p><br>\n\n<p>Questions about this study or any aspect of our protocol can be addressed to: <a href="mailto:LAMsightHelp@lamtreatmentalliance.org">LAMsightHelp@lamtreatmentalliance.org</a> .</p>\n"
msgstr "<h2> 雌激素对 LAM 的影响 </h2>\n\n<p>非常感谢您关注我们的这项研究，该研究是为了确定雌激素水平与 LAM 症状之间关系。如您所知，一些 LAM 患者的非正式报告中出指出她们的呼吸困难程度随着自己的月经周期呈现有规律的变化。但是，现有的 LAM 患者的数据中没有任何关于呼吸困难状况短期变化的线索，这使得研究者难以使用上述非正式报告来指导研究。</p><br>\n\n<p>在本项研究中，我们将使用背景问卷、定期报告以及由您操作并输入到本网站的测量数据来收集所需信息。我们将为该研究项目专门创建一个“雌激素研究”主页。我们至少需要两项测量数据：一项是家用肺活量计的读数，用于将肺功能以数字形式 (FEV1/FEC) 显示出来；另一项是体温计读数，它有助于客观地确定月经周期。由于该研究要求我们必须获得有规律而持续一致的读数，所以希望您可以选择每天接收我们的提示邮件以指导您测量数据。这些提示邮件是完全可选的，但通过这些邮件，使得我们可以收集到更为持续一致的数据。<p><br>\n\n<p>目前，我们正在进行该研究的人员招募工作以获得足够的样本患者族群。招募工作将持续到五月底，届时我们将集合所有的测试工具包以便发放到每位志愿者手中。该工具包中包含一个测量肺功能的肺活量计和一个测量基础体温以跟踪雌激素水平的体温计，以及一本介绍关于 LAM 和本项研究更广泛信息的手册。</p><br>\n\n<p>在<a href="">这里</a>可以看到本研究的完整描述。如果您希望参加研究，请点击 [这里] 以继续阅读本研究的协议和同意书并签字同意。同意书列出了您作为本研究参与者的权利、如何接收您的肺活量计和体温计以及我们如何保护您的个人信息。同意书未能涵盖的任何内容都在 LAMsight 的 <a href="">隐私政策</a> 和 <a href="">使用条款</a> 中作出了相应规定。</p><br>\n\n<p>关于该研究或协议书任何方面的提问可发送邮件至：<a href="将电子邮件发至：LAMsightHelp@lamtreatmentalliance.org">LAMsightHelp@lamtreatmentalliance.org</a> 。</p>\n"
